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Abstract 
Background: Addison`s disease (primary adrenal insufficiency) is a prototypic organ-specific 
autoimmune disease affecting the adrenal cortex. Autoimmune Addison`s disease (AAD) is 
often characterized by autoantibodies against intracellular cytochrome p450 enzymes, in 
particular 21-hydroxylase (21OH) which is central in the steroid hormone synthesis of cortisol 
and aldosterone. AAD is thought to be T-cell mediated, but these 21OH-autoantibodies 
(21OH-aab) may still play a central role. Our hypothesis is that 21OH-aab may contribute to 
an enhanced T-cell response against 21OH leading to an autoimmune attack against the 
adrenocortical cells. 
Aim: This study aimed to investigate the role of autoantibodies in antigen processing and 
presentation in the pathogenesis of AAD. 
Methods: Total IgG from patients and healthy controls were purified chromatographically 
and were detected as 21OH-aab by western blot and ELISA analyzes. The ability of 21OH-
aab to enhance T-cell responses against 21OH was evaluated in an ex-vivo interferon-gamma 
(IFN-γ) ELISPOT assay, using peripheral blood mononuclear cells (PBMC) pre-stimulated 
with 21OH protein or 21OH protein in complex with 21OH-aab. LPS-matured monocyte 
derived dendritic cells (DC) pulsed with 21OH protein alone, or 21OH in complex with 
21OH-aab were used to established short-term CD4
+
 and CD8
+
 T-cell lines. These T-cell lines 
were then tested against a 21OH peptide panel to determine if 21OH-aab could influence the 
repertoire of 21OH-derived peptides presented by DCs. Again, the production of IFN-γ, 
assayed by ELISPOT and ELISA, was used as readout for T-cell activation. In addition, the 
cytotoxic potential of the short-term CD8
+
 T-cell lines were evaluated in a lactate 
dehydrogenase (LDH) assay employing adrenocortical carcinoma cells, lymphoblastoid B cell 
lines, or autologous PBMC as targets. 
Results and conclusions: High levels of 21OH-aab was detected in Addison`s patients 
compared to healthy controls, and western blot analyzes confirmed that purified IgG-aab 
bound strongly to 21OH. The ex-vivo ELISPOT analyzes revealed an enhanced T-cell 
response in the presence of 21OH-aab. IFN-γ stimulated monocytes expressed both CD32 and 
CD64 Fcγ-receptors and blockade of these lead to a decreased T-cell response, suggesting for 
a more efficient uptake of immune complex through these receptors. However B-cells cannot 
be excluded due to their strong expression of CD32 receptors. T-cell lines induced by DCs 
pulsed with 21OH protein in complex with autoantibodies produced more IFN-γ when re-
stimulated with 21OH protein and peptides compared to T-cell lines pulsed with 21OH 
protein alone. The peptide repertoire recognized by 21OH-specific T-cell lines was also 
enhanced in the presence of autoantibodies. To conclude 21OH-aab may have an important 
role in the pathogenesis of AAD. 
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1. Introduction 
1.1 The immune system 
The immune system is a complex system with many interactions, containing numerous 
components specialized to defend the body against infections by microorganisms such as 
bacteria, viruses, fungi and parasites [1]. When a pathogen invades an organism it has to 
overcome several hindrances represented by the innate and adaptive immune system in order 
to colonize the host and cause disease [2]. The innate immune system responds fast to 
invading microorganisms and alerts the antigen specific adaptive immune system to generate 
immunological memory against microorganisms. Immunological memory is the ability for 
clones of antigen-specific lymphocytes to respond rapidly and efficiently against a previously 
encountered pathogen [1, 3]. For an adequate immune response it is therefore necessary with 
a proper communication between the innate and adaptive immune system. 
Lymphocytes have a major role in the immune system and are divided into two groups based 
on their place of development - thymus derived lymphocytes (T-cells) and bone marrow 
derived lymphocytes (B-cells) [2, 4]. Activation of lymphocytes by antigens happens in 
spleen and lymph nodes in distinctive T- and B-cells compartments. T-cells are activated 
through T-cell receptors (TCR) on their surface and are differentiated into effector cells in 
order to kill other cells or to activate or regulate a T-cell response depending on the activating 
signal [1]. B-cells may in turn be activated by T-cells after recognition of antigen by their B-
cell receptor (BCR) and are important for both long-lasting and specific protection of 
antigens. Activated B-cells may differentiate into plasma cells to produce antigen-specific 
antibodies or into specific memory cells making a protection for a secondary infection [5].  
1.1.1 The innate immune system in control of adaptive immunity 
The innate immune system consist of both cellular and molecular components with different 
effector functions, such as phagocytic cells (macrophages and neutrophil granulocytes), 
natural killer cells, acute phase proteins, cytokines such as interleukins (IL), and components 
of the complement system [2] . Furthermore, the innate immune system has two overall 
functions; to respond fast to microbes and to stimulate the adaptive immune system [2, 3]. 
The innate immune system is activated immediately during an invasion of pathogens by 
instant recognition without prior encounters with the immune system [1].  
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Invariant germ-line encoded pattern recognition receptors (PRR) contribute to discrimination 
between self- and foreign molecules by binding to conserved molecular patterns present on 
microorganisms called pathogen-associated molecular patterns (PAMP) [3, 6]. Depending on 
the function, PRR may be divided into endocytic receptors which are expressed on 
phagocytes to endocytose pathogens into lysosomes for degradation and peptide processing 
prior to presentation on the major histocompatibility complex (MHC) class II (Figure 1.1).  
Another PRR is the toll-like receptor (TLR) which also works as signaling receptors binding 
to PAMP. Toll-like receptor (TLR)-4 was the first human TLR to be identified and is essential 
for the recognition of lipopolysaccharide (LPS) [3]. LPS is one of the best known PAMP and 
is found in the cell wall of all gram-negative bacteria [6]. PAMP-activated TLR stimulate a 
transduction signal inside the antigen presenting cell (APC) enhancing the expression of 
immune-response genes. The APC will start expressing costimulatory molecules on the cell 
surface and producing cytokines and co-stimulatory molecules which in turn will activate T-
cells of the adaptive immune system [2, 3] 
 
Figure 1.1: Activation of the adaptive immune system through innate immunity. Pathogen-associated 
molecular patterns (PAMP) such as lipopolysaccharide (LPS) are recognized by pattern recognition receptors 
(PRR); endocytic receptors and Toll-like receptors (TLR) on an antigen presenting cell (APC). Pathogen is 
endocytosed and processed in lysosomes and presented as peptides on major histocompatibility complex (MHC) 
class II to a T-cell. Simultaneously cytokines are secreted and costimulatory molecules, B7, are expressed on the 
APC surface binding to CD28 to activate T-cells to proliferate and differentiate into effector cells. Reproduced 
from [3]. 
1.1.2 Adaptive immunity 
The adaptive immune system is based on clonal selection from a repertoire of lymphocytes 
bearing highly diverse antigen-specific receptors that enable the immune system to recognize 
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any foreign antigens [3]. The antigen-specific receptors, such as the TCR and the BCR, have a 
large range of variety as they are somatically generated in a process where multiple gene 
fragments are set together in several different combinations [2]. 
APC and T-cells are both involved in the initiation of the adaptive immune response. 
Processed peptides in APC are presented to T-cells and recognized trough their TCR [2]. 
Even though the adaptive primary response is slow the immunological memory provides a 
more rapid secondary response by a subsequent encounter where memory T-cells specific for 
the pathogen in question have a lower activation threshold [1]. 
1.1.2.1 How are antigens presented by antigen presenting cells to T-cells? 
Professional APC is experts in the uptake of antigens and to present them to lymphocytes to 
provide their proliferation and differentiation. Dendritic cells (DC), macrophages and B-cells 
are the main cell types involved in the presentation of antigens to naïve T-cells [2]. These 
cells vary in their means of antigen uptake, MHC class II expression and their localization 
(Table 1). 
Table 1: Antigen presenting cells[7, 8]. 
 Dendritic cell Macrophage/monocyte B-cell 
Location Organs and epithelial 
barrier tissues 
Lymphoid tissue, connective 
tissue and body cavities 
Lymphoid tissue and 
peripheral blood 
Antigen uptake Pinocytosis, phagocytosis 
by toll-like receptors 
Phagocytosis BCR-mediated uptake 
MHC class II-
expression 
Normal,  increased by 
maturation and IFN-γ 
Low or none, effected by  
IFN-γ 
Normal, increased by IL-4 
Characteristics, 
when activated 
Migration to regional 
lymphoid tissues for 
peptide-presentation of 
internalized proteins to 
naïve T-cells. 
 
Phagocytosis of microbes and 
production of cytokines, 
activating and attracting 
inflammatory cells activating 
macrophage lead to killing of 
microbe 
Antigen presentation to 
CD4
+
 helper T-cells leading 
to activation of effector T-
cells and subsequently B-cell 
activation and antibody 
production 
Immune 
response 
Clonal expansion and 
differentiation of effector 
T-cell 
Cell mediated immunity Humoral immunity 
 
Antigens may be recognized by DC in peripheral tissues trough PRR and engulfed trough 
phagocytosis [6]. The APC then become activated and up-regulates the expression of 
costimulatory molecules, such as B7 (CD80 or CD86) which together with the antigen 
receptor is necessary for lymphocyte activation [1, 2]. Activated DC migrates to local lymph 
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nodes to present processed antigen-peptide to lymphocytes through the MHC class II receptor 
[1, 2]. 
The MHC genes consist of a linked set of genetic loci encoding many of the proteins involved 
in antigen presentation to T-cells, including the MHC class I and II proteins that present 
peptides to the TCR [9]. MHC class I is expressed on all nucleated cells and peptides 
presented by these are targeted by CD8
+
 T-cells. Activated CD8
+
 T-cells will kill the target 
cell presenting the relevant peptide via MHC class I [10]. The APC are presenting 
intracellular molecules to CD8
+
 T-cells and the MHC class I are divided into isoforms A, B 
and C [1].  
MHC class II molecules are usually only expressed on professional APC and may promote T-
cell activation and differentiation. The T-cells in turn may activate B-cells to start producing 
antibodies as well as produce cytokines to help other parts of the adaptive immune response. 
DR, DQ and DP are genes coded by MHC class II and present extracellular antigens to T-cells 
[1]. 
T-cell activation requires a persistent contact between the TCR on the surface of naïve T-cells 
and the peptide presented by an MHC molecule on APC. The peptides recognized by the TCR 
are linear and seated in the groove of the MHC molecule after its antigen processing inside 
the APC [1, 11].  
The TCR is a membrane-anchored heterodimer glycoprotein containing covalently bound α-
and β-chain, where each has a constant and variable domain (Figure 1.2) [2]. The constant 
domains mediate effector functions while the variable domains are responsible for the variety 
in the antigen binding site and antigen specificity together with the CDR hyper variable loops. 
The cytoplasmic domain of the TCR are too small and lack the signal transduction activity, 
it`s non-covalently bound to CD3. CD3 consists of four polypeptide chains; γ, δ, ε and ζ, in a 
TCR complex which are required for transduction of activating signals further into the cell 
[11, 12]. 
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Figure 1.2: T-cell receptor (TCR)-complex. The TCR consists of a complex with interacting molecules 
required for both extracellular antigen recognition and intracellular signaling. The TCR consist of a heterodimer 
α- and β-chain and the CD3 complex containing four polypeptide chains; γ, ζ, ε, and δ which are important for 
the intracellular signal transduction. Modified from [13] 
1.1.2.2 Activation of T-lymphocytes 
When a TCR binds to a peptide-MHC complex tyrosine residues on the cytoplasmic domain 
of CD3 are phosphorylated, leading to a signal transduction into the nucleus (Figure 1.3, 
signal 1). Simultaneously, the co-receptor molecules CD4 or CD8 expressed on T-cells, binds 
to the MHC molecule [9].  
PAMP activation of PRR induces APC to up-regulate the expression of adhesion molecules 
CD80/86 also known as B7, leading to co-stimulation which is necessary for a stable binding 
between the two cells (Figure 1.3, signal 2) [14]. B7 expressed on APC may bind to CD28 or 
CTLA (Cytotoxic T-Lymphocyte Antigen)-4 on the T-cells. CD28 transmits a stimulatory 
response while the CTLA-4 transmits an inhibitory stimulus weakening and eventually 
turning off the T-cell response. The signal transduction explained above may activate genes 
for cytokines which are released and may in turn activate proliferation or further 
differentiation of T-cells. Secreted IL-12 from the APC binds to the IL-12 receptor on the T-
cell and may promote development of T-H1-cells or CTL which again will secrete IFN-γ when 
activated (Figure 1.3, signal 3) [11, 1]. 
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Figure 1.3: Activation of a T-cell in three steps. A T-cell is usually activated in three steps by an APC. When 
an antigen is presented on the MHC class on APC it attracts naïve T-cells which bind to the peptide-MHC-
complex. To maintain the bond between the cells for a complete activation, the APC up-regulate its expression 
of stimulating molecules such as CD80/86 (B7) against T-cell surface molecules. Depending on the antigen and 
the interacting T-cell the APC then secretes cytokines, here IL-12, which will activate the T-cell to secrete IFN-γ 
and thereby stimulate it further into effector cells. Modified from [1]. 
T-cells may be divided into two subgroups based on their expression of CD4
+
- and CD8
+
-co-
receptors interacting with MHC class II and I, respectively. CD4
+
 T-cells may be divided into 
several types of effector T-helper cells (T-H1, T-H2 and T-H17) with different functions 
(summarized in Table 2) [1]. Regulatory T-cells (T-reg) that regulate the activation of other 
T-cells also express CD4
+
-receptors and are necessary for maintaining the peripheral 
tolerance to self-antigens. CD8
+
 T-cells consist of cytotoxic T-cells (CTL) which kill infected 
cells that present peptides from intracellular viral protein and intracellular microbes bound to 
class I MHC molecules [2, 15].  
Table 2: An overview of subgroups of CD4
+
 T-lymphocytes. Activated T-cells produces large amounts of 
cytokines which is used to discriminate between the different T-cell populations. CD4
+
 T-cells are divided into 
T-H1, T-H2, T-H17 and T-reg based on their different functions and cytokine secretion profile [16-19]. 
 Effector function Secretes 
TH-1 Cell mediated immunity, Anti-tumor response and T-cell mediated 
cytotoxicity, viral and bacterial infections. May be involved in 
autoimmunity 
IL-2, IFN-γ, 
TNF-α/β 
TH-2 Humoral immunity, extracellular defense, protective against infections 
with helminthes. May be involved in allergies 
IL-4-6, IL-10, 
IL-13 
TH-17 Protective against certain bacterial and fungal infections. May be 
involved in autoimmunity  
IL-17A, IL-
17F, IL-21-22 
Treg Maintaining peripheral tolerance to self-antigens  IL-10, TGF-β 
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1.1.2.3 Activation of B-cells and production of antibodies 
B-cells are developed in the bone marrow and may work as antigen presenting cells by 
ingesting antigens and displaying them to T-cells to induce an immune response. In order to 
perform these tasks B-cells express several membrane molecules such as the BCR-complex 
which have a critical role in the antigen uptake (Figure 1.4).  
The BCR is an immunoglobulin (Ig) made up of two heavy chains and two light chains that 
are bound together by a disulfide binding [2, 20]. BCR binds extracellular antigens in 
hypervariable regions and the binding site is only 600-1700Å where only the antigenic 
epitope, which is the antigen structure recognized by the antigen receptor, will manage to fit 
[11]. Complex antigens have therefore several epitopes, like a mosaic structure [2]. 
BCR are rearranged by somatic recombination giving a great variation in antigen recognition 
as B-cells are programmed to express only one kind of antibody against a single antigen [2]. 
Circulating BCR is referred to as antigen-specific antibodies secreted by plasma cells. The 
membrane-bound BCR is associated with the signal transduction proteins Igα (CD79a) and 
Igβ (CD79b) with immunoreceptor tyrosine activation motifs (ITAM`s) on their cytoplasmic 
tails [11, 20]. ITAM enable intracellular signaling and are required for signal transduction of 
the extracellular antigen into the cell and for the transport of the BCR to the B-cell surface 
[2]. 
 
Figure 1.4: The B-cell receptor (BCR)-complex. The B-cell receptor is an immunoglobulin (IgG) with both 
variable and constant domains and is associated with Igα and Igβ (BCR) molecules in a B-cell receptor complex 
which are important for the intracellular signal transduction. Modified from[13]. 
 
Naïve B-cells circulate in peripheral lymphoid tissue and blood to encounter their specific 
antigen and maturate into effector cells. Activated B-cells migrate into germinal centers (GC) 
of the secondary follicle, areas in spleen and lymph nodes, for presentation of antigens by a 
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meshwork of follicular dendritic cells (FDC). FDC is a cell population in GC expressing high 
levels of adhesion molecules [5]. The antigen engagement lead to a cross-linkage of BCR`s 
and ITAM on the Igα/β-sheaths are brought close together and phosphorylated by the Src 
kinase family Lyn [5, 8]. Phosphorylated ITAM`s lead to signal transduction that may induce 
gene expression and internalization of the antigen. The BCR-genes have undergone somatic 
hypermutation and class switching during B-cell proliferation in response to different stimuli 
from FDC. Ingested antigen is processed within endosomes and loaded on the MHC molecule 
before it is presented on the cell surface.  
Then a helper T-cell will activate the B-cell in a cell-to-cell interaction by binding to a 
costimulatory molecule CD40 on the B-cell. Cytokine secretion by TH-cell will provide 
further activation and induce generation into memory B-cells and plasma cells (Figure 1.5) 
[5]. Memory B-cells encounter antigens in the GC and will prevent a second infection against 
an already encountered antigen [5]. Plasma cells are immunoglobulin-secreting cells and 
produce large numbers of antigen-specific antibodies which are released into the circulation to 
neutralize the encountered antigen [2]. 
 
Figure 1.5: Activation of B-cells in a T-cell dependent manner. B-cells are APC and express BCR and MHC 
class II which are recognized by an active T-cell receptor. Costimulatory molecules, CD40 and CD40 ligand 
enhance the activation together with cytokine production, here IL-10. Modified from [21]. 
1.1.2.4 Antibodies 
Antibodies are circulating proteins known for their incredible capacity in recognizing 
different structures on foreign antigens. Compared to other antigen binding structures such as 
TCR and MHC, antibodies may discriminate between multiple antigens in a wider range and 
may also bind to antigens in a greater strength [2]. 
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The antibody is made up of two identical polypeptide heavy chains and light chains bond 
together by disulfide bonds making a Y-formation with both constant and variable domains 
(Figure 1.6). The antigen binding site is localized at the N-terminal containing both a light and 
heavy chain, each with three hypervariable regions where the compositions of different amino 
acids give rise to the high diversity in antigen recognition [2].  
The antigen binding site together with a heavy and light constant domain makes the antigen 
binding fragment Fab, which if separated from rest of the antibody still may recognize 
antigens [22]. The effector functions to the antibody are localized to the constant domains of 
the heavy chain C-terminals. The amino acid sequence of the constant domain determine 
which immunoglobulin class the antibody belongs to; IgM, IgG, IgA, IgD or IgE. The 
outcome of an immune response depends on the Ig-class as they have different effector 
functions in the immune system [2]. The heavy constant domains are also known as the 
crystallizable fragment (Fc). The occurrence of antibodies may be either as membrane-bond 
to B-cells (as the BCR) or secreted in the circulation and tissue for preventing infections by 
pathogens [2]. 
 
Figure 1.6: Immunoglobulin, antigen-specific antibody. Antigen-specific antibody is made of two identical 
heavy chains (CH and VH) and two light chains (CL and VL) that are bound together by disulfide bonds (S-S). The 
Fab domain is involved in antigen recognition while the Fc domain determines the effector functions which are 
depended on the Ig class. 
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1.2 Tolerance and autoimmunity 
1.2.1 Tolerance and development of T-lymphocytes 
Tolerance is the mechanism of the immune system to control and prevent immune responses 
against self-antigens and a failure in tolerance may lead to autoimmunity. Tolerance is 
maintained during lymphocyte development where lymphocytes undergo different selection 
mechanisms to prevent maturation into autoreactive lymphocytes. Autoreactive T-cells are 
also kept in check by additional control mechanisms in the periphery [2, 23] 
Central tolerance is implemented in generative lymphoid organs; the thymus and the bone 
marrow. Initially, a positive selection step is performed to sort out the T-cells that are able to 
recognize self-MHC molecules. Next, the TCR with high affinity to self-antigens are sorted 
out by negative selection [2]. The central tolerance mechanisms will delete cells with strong 
recognition to self-antigens by apoptosis, or redirect them into T-reg lymphocytes which 
actively control responses against self-antigen in peripheral tissues [24]. 
Peripheral tolerance is related to mature lymphocytes released into circulation and may be 
induced by an incomplete T-cell activation or a continuous stimulation to self-antigens in 
peripheral organs such as spleen and lymph nodes. The outcome may be anergy, an 
unresponsive state against self-antigens leading to inactivated T-cells, or apoptosis of the 
autoreactive T-cell due to constant exposure to self-antigen [14]. 
1.2.2 Autoimmunity 
Autoimmunity is a condition where the immune system respond to self-antigens due to an 
imbalance between the immune response and tolerance [1]. A breakdown in self-tolerance 
may give raise to autoreactive lymphocytes responsible for an autoimmune response where 
self-structures are recognized and destroyed by the immune system [24, 25]. If such 
autoimmune responses persist and lead to tissue damage it`s called an autoimmune disease 
[1]. 
Autoimmune diseases have an incidence of 3-5 % in western countries [26, 27] and may be 
divided into systemic and organ-specific disorders. In systemic autoimmune diseases such as 
lupus erythematous (SLE), rheumatoid arthritis and psoriasis, antigens are not tissue-specific 
as they are expressed systemically and the disease may affect multiple organs in an individual 
[27]. Addison`s disease and type 1 diabetes (T1D) are defined as local or organ-specific 
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diseases as autoantibodies are directed against antigens produced exclusively in specific 
organs or even cells. 
Loss of tolerance and the genesis of autoimmunity, may involve both environmental and 
genetic mechanisms [27], and the autoimmune regulator (AIRE) is one of the genes that may 
cause autoimmunity when mutated. AIRE work as a transcription factor during central 
tolerance and multiple studies have determined AIRE as an inducing factor for the expression 
of TSA (tissue-restricted antigens/self-antigens) in thymus, which are crucial for the negative 
selection of T-cells [24, 25]. Even a single gene mutation in AIRE may therefore have severe 
complications as it may induce release of self-reactive T-cells [25] and lead to a reduced 
central tolerance identified as a cause of the autoimmune polyendocrine syndrome Type 1 
(APS 1) [24, 28].  
APS 1 is a recessive autoimmune disease with tissue-specific manifestations and 
autoantibodies against self-antigens in affected organs, such as 21OH in the adrenal cortex. In 
most cases the APS 1 patients have multiple disorders such as Addison`s disease, 
hypoparathyroidism or chronic mucocutaneous candidiasis [24, 29].  
1.3 Autoimmune Addison`s disease 
1.3.1 Adrenal cortex 
The adrenal glands lie right atop of the kidneys and consist of a cortex and a medulla (Figure 
1.7). The adrenal medulla produces epinephrine and norepinephrine and has a role in the 
sympathetic nervous system, while the adrenal cortex produces steroid hormones as 
mineralocorticoids, glucocorticoids and androgens. The adrenal cortex is divided into three 
histological zones: zona glomerulosa, zona fasciculata and zona reticularis. The zona 
glomerulosa produces aldosterone which participates in the organism’s salt and water 
metabolism and is also important for maintaining the blood pressure. 
Cortisol is secreted from zona fasciculata and is important for regulation of energy, bone 
metabolism and immune-cell function [28, 30]. Cortisol is secreted in response to ACTH 
secretion from the pituitary gland which again is stimulated by corticotrophin releasing 
hormone (CRH) from hypothalamus [31]. Androgens induce development and growth of 
reproductive organs in males, but the adrenal androgens play a minor role compared to 
testosterone which is exclusively produced in the testicles [31]. 
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Figure 1.7: Kidneys and different layers of the adrenal glands. Adrenal glands are localized on top of the 
kidneys with their cortex and medulla important for normal steroid hormone production in the body. Adrenal 
cortex is divided into three zones; glomerulosa, fasciculata and reticularis. Aldosterone is produced in zona 
glomerulosa important for regulation of the salt and water balance, while cortisol is released in response to stress 
by the zona fasciculata. At last androgens from the zona reticularis induce development of the male reproductive 
system, while catecholamines are secreted from medulla due to stress. Reproduced from 
[http://images.yourdictionary.com/adrenal-gland]. 
 
1.3.2 Addison`s disease 
Addison`s disease (primary adrenal insufficiency) is a prototypic organ-specific autoimmune 
disorder caused by an immunological destruction of the hormone producing cells of the 
adrenal cortex [32-34] . The adrenal medulla is not affected by the immunological attack. The 
disorder is leading to a lack of glucocorticoids and mineralocorticoids such as cortisol and 
aldosterone [31, 33, 35]. 
In 1855 Thomas Addison described the clinical features of Addison`s disease and it was often 
attributed to tuberculosis, however the use of antibiotics after the 19`th century changed this 
pattern [33, 34]. Presently 80-90 % of the causes of Addison`s disease in the Western world 
are caused by an autoimmune attack [31-33]. 
Autoimmune Addison`s disease (AAD) may occur isolated or in association with other 
endocrine autoimmune diseases [31, 34]. Almost 50 % of patients with AAD have a 
polyendocrine syndrome termed autoimmune polyendocrine syndrome type 2 (APS 2) with 
additional co-morbidities such as thyroiditis, T1D, premature ovarian failure or pernicious 
anaemia [28]. As described above, AAD may also be part of the rare disease APS 1, which 
has a prevalence of 1:90 000 in Norway [36]. 
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Addison`s disease has a low incidence, thus the total prevalence are approximately 700 in 
Norway (4.9 million population) with 144 cases per million [37]. The highest prevalence is 
found in women aged between 30-50 years, but AAD may occur at all ages [38]. The disease 
is chronic and patients need lifelong hormone therapy with glucocorticoids and 
mineralocorticoids [31]. At present, this therapy is not fully restoring  normal physiological 
hormone production [32].  
Diagnosing Addison`s patients may be a challenge as most of the symptoms are unspecific; 
nausea, abdominal pain, weight loss, vomiting and fatigue, however some characteristic 
symptoms are salt craving and hyperpigmentation in areas with scars and folds due to 
overstimulation of ACTH (Figure 1.8) [34, 37]. Characteristic symptoms of Addison’s disease 
typically occur after 90 % of the adrenal tissue is degraded and each cell layer of the cortex is 
eventually replaced by fibrous tissue [32, 34, 39]. 
 
Figure 1.8: Hyperpigmentation in folds of hands of an Addison`s patient. Modified from [28] 
1.3.3 HLA risk alleles 
The development of AAD has a clear heritability with a strong risk linkage to the Human 
leukocyte antigen (HLA) class II haplotypes DR3-DQ2 (DRB1*03-DQA1*0501-
DQB1*0201) and DR4.4-DQ8  (DRB1*0404-DQA1*0301-DQB1*0302) [33, 40], especially 
with the heterozygous combination of the DR3 and DR4.4 proteins which may induce an 
earlier disease breakout [37].  
The DRB1*0404 allele is more frequent in AAD patients compared to other DRB1*04 alleles 
[37]. DR4.4 differs from DR4.1 (the most common DR4 molecule in the healthy Norwegian 
population) in only two amino acids [41]. However, both of these are located in the peptide 
binding pocket and therefore influences which peptides that are presented from a given 
protein antigen [32, 40, 42]. 
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1.3.4 Pathogenesis 
Studies have described hyper expression of MHC class II in remaining tissue of adrenal 
cortex of Addison`s patients compared to healthy adrenal tissue. This may reflect an exposure 
to pro-inflammatory cytokines like IFN-γ, or maybe also induce enhanced activation of CD4+ 
T-cells against the adrenal cortex cells [32, 33]. Pathogenesis of AAD and the additional 
destruction of adrenal cortex are thought to be a result of three main incidents, looked into in 
Figure 1.9.  
Due to environmental stress such as infections, adrenocortical cells may die and intracellular 
21OH could be released to the extracellular environment and ingested by accumulated APC in 
the adrenal cortex (Figure 1.9, phase 1) [32]. Presentation of 21OH-peptides through MHC 
class II and I will activate CD4
+
 and CD8
+
 T-cells in lymph nodes, which may start an 
activation of autoreactive T- and B-cells with production of 21OH-aab (Figure 1.9, phase 2). 
This again may result in a highly specific and integrated immune response against the adrenal 
cortex with cytotoxic CD8
+
 T-cells, together with autoantibodies and the complement system 
as mediators in the destruction of the adrenal cortex (Figure 1.9, phase 3)[32, 33]. 
 
Figure 1.9: Pathogenesis of Autoimmune Addison`s disease. Adrenocortical cells may suffer from 
environmental stress or virus infections which may lead to cell death and release of intracellular 21OH. 21OH 
will in turn be ingested by APC that travel to local lymph nodes and present peptides to T-cells. Autoreactive T- 
and B-cells may go through clonal expansion and for instance start production of 21OH-autoantibodies which 
may attack own adrenal cortex tissue together with CD8+ T-cells, macrophages secreting free radicals, 
complement system or by cytokines produced by CD4+ T-cells inducing apoptosis. Reproduced from 
[32]. 
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1.3.5 Autoantibodies 
Autoimmune diseases are often characterized by specific autoantibodies which may have a 
role in the pathogenesis of the disease [23, 26]. In Addison`s disease autoantibodies against 
intracellular cytochrome p450 enzymes of the steroid synthesis in adrenal cortex are found 
and used diagnostically; 21-hydroxylase (cytochrome p450c21, 21OH), 17α hydroxylase 
(p450c17, 17OH) and cholesterol side chain-cleaving enzyme (p450cSCC, SCC). These 
enzymes are expressed in all layers of adrenal cortex, and 17OH and SCC are in addition 
produced in all steroid producing cells such as in testes and gonads [29, 43]. 21OH, which is 
exclusively expressed in the adrenal cortex, is the dominant antigen, confirmed recently in a 
large Norwegian cohort where 86 % of 426 patients had 21OH-aab [37]. 
21OH (54 kDa [35] or 55 kDa [44]) is an intracellular enzyme associated with the 
endoplasmic reticulum (ER) membrane and important for steroid synthesis of cortisol and 
aldosterone [28, 40, 45, 46]. 
Several studies have shown that the antibodies against 21OH and the adrenal cortex predict 
the clinical onset of AAD [34, 47] . Boe et al. [29] determined that the 21OH specific 
autoantibody in the adrenal cortex is a IgG1 subtype. IgG1 in humans is associated with 
activation of TH-1 cells which are involved in e.g cell mediated immunity (Table 2). In 
addition, the Fc-domain of IgG may bind to Fcγ-receptors (FcγR`s) expressed on phagocytic 
cells; FcγR I (CD64), II (CD32) and III (CD16), and trigger biological functions such as 
phagocytosis and endocytosis [11, 48]. Such activation may lead to peptide presentation by 
MHC class I or II which may in turn activate effector T-cells binding to this peptide-MHC 
complex [49]. However, CD16 are also expressed on natural killer (NK)-cells and may be 
involved in antibody-dependent cell mediated cytotoxicity (ADCC) rather than increased 
phagocytosis of 21OH immune complexes [48]. 
Taken together, IgG1 autoantibodies against 21OH may be involved in destructive processes 
against the adrenal cortex in AAD [29, 32]. However, the overall function of these 
autoantibodies in AAD is still unknown and more research is needed to investigate different 
mechanisms that 21OH-aab may be involved in. Instead, T-cell mediated autoimmunity is 
assumed to be the major cause of AAD and 21OH are indeed targeted by antigen-specific T-
cells [40]. 
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1.4 Aim of the study 
In a previous study [40] a considerable increased T-cell response against 21OH was observed 
when cells from Addison`s patients were stimulated in the presence of autologous plasma 
containing 21OH-aab. As AAD is believed to be T-cell mediated, the question is which role 
these 21OH-aab have in the mechanism behind the development of the disease. 
The main aim of this study was to investigate if 21OH-aab in Addison`s patients may enhance 
the T-cell response against 21OH and thereby amplify a specific immune response against the 
adrenal cortex. 
 
Several objectives were set to solve this aim: 
1. Detect and purify 21OH-autoantibodies in Addison`s patients 
2. Determine which APC that activates a T-cell response against 21OH and by which 
Fcγ-receptors on APC the immune complexes are taken up 
3. Investigate which peptides of 21OH that are presented by APC and activates a T-cell 
response 
4. Investigate if target cells express similar HLA molecules as effector CD8+ T-cells by 
flow cytometry and immunofluorescence 
5. Determine if cytotoxicity is increased due to an enhanced T-cell response by 
stimulation of DC with CD8
+
 T-cells and 21OH peptide derivate 
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2. Materials  
To this project samples from patients with autoimmune Addison`s disease (AAD, n=34) were 
collected from a local bio bank (ROAS) at the Medical department at Haukeland University 
Hospital. Control samples were collected from blood donors (from here named healthy 
controls) (n=13) at the Blood Bank at Haukeland University Hospital. A written agreement 
approved by the Committee of Ethics at the University of Bergen confirmed that patients and 
healthy controls consented to research. Addison`s patients selected for this study were based 
on the presence of 21OH-aab, both high and low levels as measured by a fluid phase 
radioimmunoassay (RIA) [50]. 
Recombinant 21OH (~54 kDa, 130 µg/ml in sterile PBS) was purified as described [51]. 
Briefly, the cDNA encoding 21OH was cloned into the genome of baculovirus with a 
hexahistidin-tag on the N-terminal, where histidine binds to divalent metal ions such as 
nickel. Insect cells (Spodoptera frugiperda, Sf.) infected with baculovirus were lysed to 
isolate 21OH after separation of cytosol and cell membrane, and the recombinant 21OH was 
purified by immobilized metal ion affinity chromatography [51]. The 21OH sequence is 
displayed in appendix 6.1. 
HLA genotypes from some of the patients were available from a previous study [52]. 
2.1 Materials for LDS-PAGE and western blot 
Name  Manufacturer Catalogue nr. 
NUPAGE®LDS Sample Buffer (4x) Invitrogen™ NP0007 
NUPAGE® Reducing Agent (10x) Invitrogen™ NP0009 
NuPAGE®10 % Bis-Tris Gel 1.0 x 15 well Invitrogen™ NP0303BOX 
SeeBlue®Plus2 Prestained Standard (1x) Invitrogen™ LC5925 
MagicMark™xp Western Standard Invitrogen™ LC5603 
Simply Blue™ SafeStain Invitrogen™ LC6060 
iBlot Gel Transfer Stacks PVDF mini Invitrogen™ IB4010-02 
MOPS SDS Running Buffer (20x) Invitrogen™ NP0001 
NUPAGE®Antioxidant Invitrogen™ NP0005 
Immobilon™ Western Chemiluminescent 
AB substrate Millipore WBKDS0100 
BCIP (100x) Biorad 170-6532 
NBT (100x) Biorad 170-6539 
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2.2 Buffers for SDS-PAGE, western blot, ELISA and 
immunofluorescence 
Name  Content 
Wash buffer, PBS-T  PBS, 0.05 % (v/v) Tween-20 
Block solution (ELISA) PBS-T 3% BSA 3 % (v/w) BSA in PBS-T  
FC-buffer PBS 1 % BSA 
Running buffer I: 40 ml MOPS SDS Running buffer (20X) 
  760 ml Milliq-H2O 
II: 200 ml Running buffer I  
     500 µl NUPAGE
®
Antioxidant 
Developing buffer 0.1M NaHCO3, 1mM MgCl2 in ddH2O at pH 9,8 
Blocking solution, WB 5 % v/w Non-Fat Dry Milk.  PBS-T 
4% (v/v) Paraformaldehyde in PBS  Made prior to the study and stored at -20 °C 
 
2.3 Materials for IgG purification, ELISA, ELISPOT and cytotoxicity 
analysis 
Name  Manufacturer Catalogue nr. 
Protein A HP SpinTrap kit GE Healtcare 28-9031-32 
Ab Buffer kit GE Healthcare 28-9030-59 
DEPC Treated Water Invitrogen™ 46-2224 
p-Nitrophenol phosphate substrate 
solution 
SIGMAFAST™ N1891 
ELISA MAX™ Deluxe Sets Human 
IFN-ɣ 
BioLegend 430104 
Nunc-Immuno™ 96-well flat-bottomed 
plates with Maxi Sorp™ 
Thermo Fischer Scientific 442404 
ELISpotPRO for Human IFN-ɣ kit Mabtech 3420-2AST-2 
LDH Cytotoxicity Assay Kit Cayman Chemical Company 10008882 
 
2.4 Antibodies 
Name Dilution Manufacturer Catalogue nr. 
AP-conjugated goat Anti-human 
IgG (γ-chain specific) 
1:2000, 
1:5000 
Sigma-Aldrich™ A3187 
AP-conjugated donkey Anti-
Goat IgG 
1:5000 Santa Cruz Biotechnology Sc-2022 
mouse Anti-human CD32 
Functional grade purified 
1:100 eBioscience 16-0329 
mouse Anti-Human CD64 (Fc 
gamma receptor 1) Functional 
grade purified 
1:100 eBioscience 16-0649 
goat Anti-Human 21OH 1:200 Santa Cruz Biotechnology Sc-48466 
Unconjugated mouse Anti-
Human HLA-A2 
2 µg BioLegend 343301 
Alexa488 Fluor® donkey Anti-
Mouse IgG (H+L) 
1:200 Invitrogen™ A21202 
FITC-conjugated mouse Anti-
Human HLA-A2 
1:5 Biolegend 343303 
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2.5 Materials for cell culture 
Name  Manufacturer Catalogue nr. 
Ficoll-Paque™ Plus GE Healthcare 17-1440-02 
Trypan Blue stain 0.4 % with Countess®  Invitrogen™ T10282 
X-VIVO 15 Lonza BE04-418F 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich® D8418 
Human Sera Type AB (male) plasma 
derived Bio Wittaker® 14-191E 
MACS™ BSA Stock Solution Miltenyi Biotec 130-091-376 
autoMACS™ Rinsing Solution Miltenyi Biotec 130-091-222 
MACS® Separation Columns 25 MS 
Columns Miltenyi Biotec 130-042-201 
MACS Separator Miltenyi Biotec - 
CD8 MicroBeads, human Miltenyi Biotec 130-045-201 
CD4 MicroBeads, human Miltenyi Biotec 130-045-101 
CD14 MicroBeads, human Miltenyi Biotec 130-050-201 
Dynabeads®CD19 pan B Invitrogen™ 111.43D 
DETACHaBEAD® CD19 Invitrogen™ 125.06D 
GM-CSF (100x) Biolegend 572904 
IL-4 (50x) Biolegend 574006 
LPS (1000x) Sigma-Aldrich L1887 
IL-7 eBioscience 34-8079-82 
IL-2 Peprotech 200-02 
Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham Sigma-Aldrich® D2906-1L 
Na2CO3 Sigma® S-5761 
BD Nu-Serum BD Bioscience® 355100 
ITS+ BD Bioscience®  354352 
RPMI 1640 without L-Glutamine Lonza BE12-167F 
L-Glutamine 100x Lonza 17-605E 
FBS 100x Life Technologies 10108-165 
Hepes Buffer 1M Bio Wittaker® BE17-737E 
PEN-STREP 10.000 U Penicillin/ml Bio Wittaker® DE17-602E 
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2.6 Apparatus and Equipment’s 
Name Manufacturer 
5702 Centrifuge  Eppendorf 
5810 R Centrifuge  Eppendorf 
BD Accuri® C6 Flow Cytometer BD Accuri Cytometers 
CO2 Incubator Sanyo 
EPS 2A200  Hoefer 
FluroChem® HD2 Chemiluminescence Alpha Innotech 
iBlot™ Device Invitrogen™ 
Infinite® M200 microplate reader Tecan 
LSM 510 META Microscope Zeiss 
ND-1000 Spectrophotometer Nano®Drop 
Protean II Multiscreen apparatus Biorad 
Scanlaf Mars Class 2 Safety Cabinet Lab-Tec 
Spectramax Plus Spectrophotometer Molecular Devices 
Vibramax 100 rotating platform Heidolph Instruments 
 
2.7 Software 
Name Purpose 
GraphPad Prism 5 Graph production and statistical analysis 
Adobe Photoshop CS5 Picture modification 
Adobe Illustrator CS5 Figure production 
LSM Image Browser Immunofluorescence images 
Zeiss LSM 510 Software Immunofluorescence analysis 
CFlow®Sampler Analysis Flowcytometry modification 
CTL ImmunoSPOT Analyzer ImmunoSpot Software for ELISPOT Analysis 
 
2.8 Miscellaneous 
Name  Manufacturer Catalogue nr. 
PBS Tablets Invitrogen® 18912-014 
Phosphate Buffered Saline, PBS Bio Whittaker® BE17-516F 
Bovine serum albumin (BSA) Sigma
®
 A7030-100G 
Tween-20 Cayman Chemical company 400035 
Triton X-100 Sigma-Aldrich® T9284 
FBS  Life technologies 10108-165 
H2SO4 1 M Merck  
Nuclease Free Water Ambion® AM 9932 
FcR Blocking Reagent, human Miltenyi Biotech 130-059-901 
ProLong® Gold antifade reagent 
with DAPI 
Invitrogen™ P36935 
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3. Methods 
3.1 Detection of 21OH-autoantibodies  
In order to identify patient plasma with high levels of 21OH-autoantibodies (21OH-aab), an 
in-house ELISA was performed essentially as described [51]. Briefly, Nunc-Immuno™ 96-
well flat-bottomed plates with Maxi Sorp™ surface were coated with 100 µl 21OH protein (5 
µg/ml in PBS). After incubation at 4 °C overnight, excess protein solution were decanted and 
blocking solution were used to block unspecific binding sites for 30 minutes at 37 °C. Plates 
were washed four times with wash buffer before 100 µl plasma samples (1:100) diluted in 
blocking solution were pipetted in duplicates or triplicates on the 96-well plate. Plasma 
samples were incubated on shaking platform for 1 hour at room temperature (RT) or 
overnight at 4 °C.  
Subsequently, the plate was washed four times with wash buffer and incubated with alkaline 
phosphatase (AP)-conjugated goat Anti-Human IgG (1:2000) for 1 hour at RT on a shaking 
platform. After five final washes in wash buffer, visualization of immune complexes by p-
Nitrophenol phosphate substrate solution was performed and incubated in the dark for 10- 30 
minutes and the optical density was measured at 405 nm by a SpectraMax Plus 
spectrophotometer. For each plate, a cut-off value distinguishing between plasma samples 
positive and negative for 21OH-aab were calculated from a series of 12 healthy controls, 
using the mean OD values from these plasma samples tested in parallel, plus 3 standard 
deviations (SD). 
3.1.1 LDS-polyacrylamide gel electrophoresis (LDS-PAGE) and Western 
blotting 
Western blotting was performed to confirm that 21OH-aab detected by ELISA were present in 
patient plasma, and that purified IgG still contained 21OH-aab. Different sources of 21OH-
containing protein lysates were prepared for electrophoresis with NuPAGE
®
LDS Sample 
buffer (4x) and NuPAGE
®
Reducing agent (10x) using the NUPAGE
®
Novex
®
 Bis-Tris Mini 
Gels protocol, and boiled at 70 °C for 10 minutes.  
Further, the 21OH-lysates were separated on a NuPAGE
®
10 % Bis-Tris SDS gel running at 
180 V for 1 hour and blotted using the iBlot Gel Transfer Stacks PVDF mini Kit (program 3, 
7 minutes, 20 Volt). The membrane was blocked with 5 % milk buffer overnight at 4 °C on a 
shaking platform and incubated with primary antibodies (patient or control plasma, purified 
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IgG or a commercial goat Anti-Human 21OH antibody at appropriate dilutions for 2 hours at 
RT on a shaking platform. After washing three times with PBS-T for 5 minutes, the 
membrane was incubated with secondary antibodies AP-conjugated goat Anti-human IgG 
(1:5000) or AP-conjugated donkey Anti-Goat IgG (1:5000) for 1 hour at RT on a shaking 
platform.  
The membrane was washed as described above and antigen-antibody complexes were 
visualized by Immobilon™ Western chemiluminescence AP substrate at Fluor chem®HD2. 
Alternatively, a colorimetric method was also used where the membrane was washed 3 more 
times in PBS-T for 5 minutes and 2 times 5 minutes in developing buffer. Finally, the NBT 
(100x) and BCIP (100x) substrate was added, and the membrane was developed for 
approximately 5 minutes until bonds were visible. 
3.1.2 Purification of IgG antibodies 
IgG from patient plasma was purified by a Protein A HP SpinTrap kit, using spin columns 
with Protein A Sepharose™ which have a strong affinity to IgG, especially human IgG1. The 
purification was carried out exactly as described by the manufacturer.  
Briefly, medium in the spin column was suspended and centrifuged at 70 x g for 30 seconds. 
The column was then equilibrated by adding Binding buffer followed by another 
centrifugation at 70 x g for 30 seconds. The columns were loaded two times with 600 µl of 
serum and incubated 4 minutes with gentle mixing before centrifugation at 70 x g for 30 
seconds. Subsequently, the columns were washed twice in Binding buffer and centrifuged at 
70 x g for 30 seconds.  
Finally, Elution buffer was added (400 µl) to release IgG from the column and the spin 
columns was transferred to tubes with Neutralizing buffer and then centrifuged at 70 x g for 
30 seconds two times to collect the IgG in two fractions. IgG antibody concentration was 
measured by UV-light absorption at 280 nm on a Nano
®
Drop ND-1000 Spectrophotometer 
and a correction factor at 0.72 was used to calculate the final IgG concentration (mg/ml). 
Immune complexes of IgG autoantibodies and 21OH (130 µg/ml) were prepared by 
incubating the two in a 2:1 molar ratio for 1 hour at RT. This corresponded to 250 µg/ml of 
purified IgG and 2.5 µg/ml 21OH. 
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3.2 Cell culture 
3.2.1 Isolation of peripheral blood mononuclear cells (PBMC) for in vitro 
assays 
PBMC was separated from venous blood by differential density centrifugation by Ficoll-
Paque PREMIUM medium with a density of 1.077 g/ml. Anticoagulant-treated blood 
(heparin) was mixed with an equal volume of PBS, layered carefully over Ficoll-
Paque™PLUS medium in a 4:3 ratio and centrifuged at 400 x g for 40 minutes. The upper 
layer was drawn off leaving the mononuclear cells on top. Carefully the mononuclear cell 
layer was transferred to a new centrifuge tube and 3 times the volume of PBS was added. The 
tube was centrifuged at 300 x g for 10 minutes, supernatant was decanted and cells suspended 
in 10 ml PBS.  
Viable cells were counted using Trypan Blue Stain in a Bürker counting chamber. 
Simultaneously, the cell suspension was centrifuged at 300 x g for 10 minutes before being 
resuspended in growth medium. PBMC from AAD patients and controls were grown in 
serum-free X-VIVO 15 medium at 37 °C with 5 % CO2 and 95 % humidity. 
Freezing of cells was done directly after cell separation from venous blood in 10 % (v/v) 
DMSO and 90 % (v/v) AB serum, first at -80 °C for 24 hours, thereafter at -150 °C. 
3.2.2 Ex-vivo ELISPOT 
T-cell responses were measured by IFN-γ ELISPOT after pre-stimulation with 21OH alone or 
21OH/IgG immune complexes. This method is very specific and sensitive and yields both 
qualitative and quantitative results.  
Cryopreserved PBMC from AAD (stored at -150 °C) was thawed in a water bath preheated to 
37 °C and suspended in preheated X-VIVO 15 medium and centrifuged at 300 x g for 10 
minutes. The pellet was suspended in 10 ml X-VIVO 15 and viable cells were counted as 
described above. Simultaneously the complete cell suspension was centrifuged at 300 x g for 
10 minutes and the pellet was suspended to contain 5 x 10
6
 cells per ml. Cell suspensions 
containing 1 million PBMC`s (200 µl) were rested for 12-24 hours in 37 °C and 5 % CO2 
before pre-stimulation. 50 µl of medium only, 21OH (2.5 µg/ml) alone, IgG alone (250 
µg/ml) or 21OH/IgG immune complexes were added the next day, and the cells were pre-
stimulated for 24 hours.  
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For experiments detecting the importance of Fcγ-receptors Anti-Human CD32 and CD64 was 
incubated with PBMC for 1 hour to block these receptors prior to addition of immune 
complexes.  
ELIspot
PRO
 kit for Human IFN-ɣ was used to perform the ELISPOT analyzes. ELISPOT wells 
were washed 4 times with PBS and then blocked with 10 % Human Sera Type AB in X-
VIVO 15 for 30 minutes at RT to prevent unspecific binding to the membrane. Cell pellets 
from pre-stimulation were suspended twice in 1 ml X-VIVO 15 after centrifugation at 300 x g 
for 10 minutes and 200 x g for 8 minutes. Finally, the cell pellet was suspended in 600 µl X-
VIVO 15 and transferred at 150 µl in triplicates or quadruplicates to the ELISPOT plate for 
24 hours incubation in 37 °C and 5 % CO2, with aluminum foil wrapped around it. 
Supernatants from selected pre-stimulation steps was saved for ELISA analyzes and frozen at 
-20 °C. 
The ELISPOT wells were decanted and washed 5 times in 200 µl PBS before it was incubated 
with secondary antibody 7-BG-ALP (1:200) in 0.5 % FCS for 2 hours at RT wrapped in 
aluminum foil. A second wash with PBS was performed, before incubation with BCIP/NBT-
plus substrate for 5-15 minutes and a final wash in tap water to stop the chromogenic reaction. 
The plate was dried and spots were counted manually in a microscope or by the use of C.T.L 
ImmunoSPOT automated scanning software at The Gade Institute at UoB. 
3.2.3 Cell isolation from PBMC 
3.2.3.1 Magnetic cell sorting (MACS) of CD4+, CD8+ and CD14+ 
MACS is based on a method which magnetically labels co-receptors on cells with respective 
MicroBeads, which are conjugated to monoclonal mouse Anti-Human CD4, CD8 or CD14 
antibodies. Purification of selected cells was performed according to the manufactures protocol. 
PBMCs were counted as described previously (chapter 3.2.1), centrifuged at 300 x g for 10 
minutes and supernatant was completely removed. The cell pellet was suspended in 80 µl 
buffer per 10
7
 cells and 20 µl MicroBeads per 10
7
 cells were added before mixing and 
incubation at 4-8 °C for 15 minutes. Next, cells were washed in 1-2 ml buffer per 10
7
 cells 
and centrifuged at 300 x g for 10 minutes and supernatant was again completely removed. 
The pellet was then suspended in 500 µl buffer.  
An MS column was placed on a magnetic board together with the MACS Separator magnet 
and equilibrated with 500 µl buffer before addition of the cell suspension. The unlabeled cells 
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run through the column while target cells stay in the magnetic field because of the binding to 
magnetic MicroBeads. A three-step wash with 500 µl buffer was performed, and the column 
was removed from the MACS Separator and placed on a suitable tube while 1 ml buffer was 
added to elute the positively selected cell fraction. 
3.2.3.2 B-cell purification 
B-cells express co-receptor CD19 [5] and were isolated from PBMC by superparamagnetic 
polysterene Dynabeads
®
 coated with monoclonal CD19 antibodies. Dynabeads
®
 CD19 pan B 
and DETACHaBEAD
®
 CD19 protocols was followed exactly as described by the 
manufacturer.  
Briefly, Dynabeads
®
 were washed prior to usage and adequate amounts (25 µl) were added to 
prepared PBMC (1 ml) and incubated on shaking platform for 20 minutes at 2-8 °C. A 
magnetic field was used to wash the bead-bound cells 4 times with buffer. Purified cells were 
then resuspended in culture medium following the DETACHaBEAD CD19 protocol to attach 
the magnetic beads and release bead-free CD19
+
 cells.  
DETACHaBEAD CD19 contain Anti-Fab polyclonal antibodies specific for CD19 antibodies 
coated on Dynabeads and may detach Dynabeads from CD19
+
 cells in use of a magnetic field. 
DETACHaBEAD (10 µl) was incubated with CD19-coated PBMC for 45 minutes on shaking 
platform in RT and washed 3 times in medium. Supernatants containing bead-free cells were 
pooled and collected for further examination. 
3.2.4 Establishment of T-cell lines 
In order to induce T-cell lines (TCLs) specific for 21OH, we first differentiated monocytes 
from PBMC into dendritic cells (DCs) to be used as antigen presenting cells (APC): A PBMC 
cell suspension was transferred to a 6-well plate (5 x 10
6
 cells in 3 ml) and incubated at 37 °C 
in 5 % CO2 for 75-90 minutes in X-Vivo 15 medium. The medium containing non-adherent 
cells was then aspirated and the remaining adherent cells were washed twice with preheated 
X-VIVO 15 medium.  
The adherent cells were cultured with cytokines to promote differentiation of monocytes into 
DC. The cells were incubated with IL-4 (1000 U/ml) and GM-CSF (1000 U/ml) for 6-8 days 
and every third day half of the medium was replaced with medium containing fresh cytokines. 
After 6-7 days, the resulting immature DCs were resuspended by pipetting and washed twice 
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with X-VIVO 15. Cells were counted as described above and the pellet was suspended in X-
VIVO 15 (450 µl per well) and transferred to a 24-well plate.  
The immature DC`s were loaded with 21OH alone or 21OH/IgG immune complexes, and 
incubated for 1-3.5 hours before LPS (1 µg/ml) was added for 24 hours to induce mature 
DC`s presentation function. Autologous PBMC or purified CD4
+
- or CD8
+
 T-cells were then 
added at 2 x 10
6
 cells/ml to the mature DC`s. Two days later IL-2 (10 IU/ml) and IL-7 (10 
µg/ml) were added (only IL-2 was used for CD4
+
 T-cells). The responding T-cells were then 
cultured for 10–18 days, with replacement of medium including cytokines and splitting as 
required. 
3.2.4.1 ELISPOT analysis of T-cell lines 
ELISPOT with the TCLs was performed to determine if cells stimulated several times with 
antigen and cultured for a longer period would give an enriched T-cell response compared to 
cells tested ex-vivo. After 10-18 days of culturing following priming with mature DCs, the 
TCLs were tested against 21OH protein, as well as against 21OH-derived peptides (displayed 
in appendix 6.2). 
In addition to provide information about the enrichment of 21OH-specific T-cells, the use of 
peptides would also reveal any differential recognition of 21OH epitopes following priming 
against 21OH alone, or 21OH/IgG immune complexes. The ELISPOT assay was then set up 
exactly as described above (3.2.2), except that the pre-stimulation step was omitted. Instead, 
the autologous PBMC or BCLs were pulsed with peptides or protein for 1-12 hours, and used 
as APC. The APC (1-2 x 10
5
) were then suspended into the ELISPOT wells along with 1-2 x 
10
5
 T-cells. 
3.2.5 Cytokine enzyme-linked immunosorbent assay (ELISA) 
ELISA was performed to measure quantitative amounts IFN-ɣ secreted into culture by 
activated T-cells. 100 µl cell culture media was tested in sandwich ELISA, exactly as 
described by the manufacturer’s protocol. All incubation steps were performed on a shaking 
platform in RT.  
Briefly Capture Antibody (1:200) was diluted in Coating Buffer and incubated overnight at 4 
ºC on a 96 well plate from the kit. Subsequently, supernatants was discarded and plate was 
washed 4 times with Wash Buffer (400 µl) prior to incubation with 1X Assay Diluent (200 µl) 
for 1 hour to reduce background and block unspecific binding. The plate was washed another 
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4 times before prepared standards and patient plasma (100 µl) was added and incubated for 2 
hours. Next, the plate was washed 4 times and Detection Antibody solution was added and 
incubated for 1 hour before a new 4 step wash and addition of Avidin-HRP solution (1:1000) 
diluted in 1X Assay Diluent incubated for 30 minutes.  
Plate was washed 5 more times for 30-60 seconds to minimize background and added mixed 
TMB Substrate Solution and incubated for approximately 15 minutes in the dark. At last Stop 
solution (2 N, H2SO4) ended the reaction and absorbance was measured at 450 nm within 30 
minutes at Spectramax Plus. IFN-γ concentration (pg/ml) was calculated from a logarithmic 
standard curve. 
3.3 Measurement of T-cell cytotoxicity 
3.3.1 Culturing H295R human adrenocortical carcinoma cell line 
NCI-H295R was cultured in prepared supplemented medium containing; Dulbecco’s 
Modified Eagle’s Medium/Nutrient Mixture F-12 Ham with HEPES buffer (15 mM) added 
Na2CO3 (1.2 g/L), Nu-serum (2.5 %) and ITS+ (1 %), in culture condition 37 ºC with 5 % 
CO2. Cells were grown to about 90 % confluence and sub-cultivated at a 1:3-4 ratio. 
3.3.2 Culturing lymphoblastoid B-cell lines 
Lymphoblastoid B-cell lines (PGF and PRIESS) were cultured in RPMI 1640 medium 
containing fetal bovine serum (10 % v/v), L-glutamine (100x, 1 % v/v), Hepes buffer (1 M, 1 
% v/v) and antibiotics (PEN-STREP, 10000 U/ml, 1 % v/v) at 37 ºC with 5 % CO2. The B-cell 
lines (BCLs) were handled and thawed in the same way as PBMC and PGF cells was used as 
antigen presenting cells or target cells in cytotoxicity assays. For cell-culture passage, the 
BCLs were maintained at 3-10 x 10
5
 per ml and split at 1:3-4 every third day.    
3.3.3 Detection of HLA genotype by immunofluorescence on NCI-H295R cells 
Immunofluorescence was performed to investigate if NCI-H295R cells express HLA class I, 
A2 molecules on their surface.  
NCI-H295R cells were cultured on coverslips (10
6
 cells per/well in 24-well plate) for 24 
hours. The coverslips were washed with PBS (1 ml) and fixated with 4 % paraformaldehyde 
in PBS for 10 minutes in RT. A new wash was performed with BSA (3 % v/w in PBS), before 
blocking with 10 % (v/v) FBS in PBS for 1 hour at RT. Wells were washed with  1 % (w/v) 
BSA in PBS and added Mouse Anti-Human HLA-A2 (1 and 2 µg) diluted in 1 % (w/v) BSA 
in PBS incubated for 1 hour at RT.  
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After washing, Alexa488-conjugated donkey Anti-Mouse was added at 1:200. Cells were 
washed 3 times in 1 % (w/v) BSA in PBS and coverslips were washed in water and excess 
liquid was removed before mounting coverslips with a drop of ProLong Gold with DAPI on a 
microscope slide. The preparation was allowed to harden for at least 24 hours in dark before 
analyzed on a confocal microscope, Zeiss LSM 510 META, at the MIC platform, UoB. 
3.3.4 Identification of Fcγ-receptors on APC by flow cytometry 
Flow cytometry was used to detect expression of Fcγ-receptors (II: CD32 and I: CD64) on 
APC`s and HLA class I A2 on NCI-H295R and PRIESS cells. 
Cells were cultured for approximately one week; they were counted and split during this 
period. Prior to the flow cytometry analysis cells were stimulated with IFN-γ (0.5 µg/ml) to 
turn up HLA-I and Fc-receptor expression. Subsequently, cells were counted as described 
above (chapter 3.2.1), centrifuged at 300 x g for 10 minutes, washed in PBS and resuspended 
in FC-buffer. Cell suspension was pipetted into tubes (100 µl, 1x10
6
 cells/ml) and APC`s was 
added Fc-blocker (1 µl), incubated for 5-10 minutes in RT to bind and occupy the Fcγ-
receptor seats.  
Further, primary antibodies, mouse Anti-Human CD32 and CD64 (1:100) and FITC-
conjugated mouse Anti-Human HLA-A2 (1:5), were added cells and mixed well before 
incubation on ice for 30 minutes. Cells were suspended in 2 ml FC-buffer and centrifuged at 
400 x g for 5 minutes, supernatants were discarded and the cell pellet was resuspended in FC-
buffer (100 µl). For APC the secondary antibody, Alexa488-conjugated donkey Anti-Mouse 
IgG (1:200), was added and incubated on ice for 30 minutes covered with aluminum foil due 
to light sensitive secondary antibody. At last, cells were washed in FC-buffer (200 µl) and 
stored in fridge covered with aluminum foil until analyzed on the AccuriC6 instrument. 
3.3.5 Cytotoxicity of cultured CD8+ T-cells 
The ability of cultured CD8
+
 T-cells to induce cytotoxicity was measured with the LDH 
Cytotoxicity Assay Kit. NCI-H295R cell-line or autologous PBMC`s were used as target cells 
pulsed with 21OH peptides. 
Target cells were counted and transferred (100 µl) to a 96 well plate and incubated overnight 
at 37 °C and 5 % CO2 before peptide pools (10µg/ml) of 21OH were added (for PBMC). 
CD8
+
 T-cells was centrifuged at 300 x g for 10 minutes, suspended in X-VIVO 15 and 
counted as described above (chapter 3.2.1). Target cells, peptide pools and CD8
+
 T-cells at 
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different ratios were incubated for 4 hours in 37 °C and 5 % CO2. Different ratios of CD8
+
 T-
lymphocytes against target cells were used to determine if there was a dose response in 
cytotoxic activity with more CD8
+
 T-cells.  
Standards were made before usage and pipetted into a new 96 well plate as duplicates. As 
positive controls, cells were added 0.2 % Triton X-100, and mixed for 10 minutes before 
centrifuged at 400 x g for 5 minutes. Supernatants were transferred to the new plate with 
standards and LDH Reaction solution was added and incubated for 30 minutes at RT. The 
absorbance was read at 490 nm on a spectrometer and the LDH activity (µU) was calculated 
by the linear equation using the logarithmic and blank subtracted absorbance values. 0.2 % 
Triton X-100 was used a positive control for maximum cytotoxicity. Target cells alone were 
used as a control for spontaneous LDH release.  
3.4 Statistical analyses 
A two-tailed paired T-test was done to detect a significant difference between cells treated 
with various pre-stimuli where p values less than 0.05 was considered significant.  
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4. Results 
In a previous study we have observed a considerable increased T-cell response against 21OH 
in Addison`s patients, when stimulated in the presence of autologous plasma containing 
21OH-autoantibodies (21OH-aab). As autoimmune Addison’s disease is believed to be T-cell 
mediated, the question is which role 21OH-aab have in the mechanism behind the 
development of the disease. 
4.1 Detection of 21OH-autoantibodies in plasma of Addison`s patients 
Addison`s patients are characterized by antibodies against 21OH, where 21OH is exclusively 
expressed in the adrenal cortex. Initially, we determined levels of 21OH-aab in AAD patients 
and healthy controls by ELISA in order to identify patients with high levels of 21OH-aab for 
further experimentation (Figure 4.1). An expected and significant (p < 0.0001) higher 
absorbance was measured in AAD patients compared to healthy controls, although large 
individual differences between patients were noted. 
A
dd
is
on
's
H
ea
lth
y 
co
nt
ro
ls
0.0
0.2
0.4
0.6
0.8
1.0
1.2
***
A
b
so
rb
a
n
c
e
 4
0
5
 n
m
 
Figure 4.1: ELISA analysis detected high levels of 21OH-autoantibodies in plasma of Addison`s patients. 
21OH protein samples (5 µg/ml) was coated on 96-well flat-bottomed plates and incubated with plasma from 
AAD patients (n=12) and healthy controls (n=12). After adding AP-conjugated Anti-Human IgG secondary 
antibody and chromogenic substrate, optical density was measured at 405 nm with two parallels per sample. The 
average of all samples in each group is displayed by the dark line, with error bars representing the standard 
deviations for each group. The dotted line is 3 standard deviations above the average of controls and indicates 
the cut-off value between samples negative and positive for 21OH-aab. The graph represents one independent 
experiment where a two-tailed unpaired T-test show a significant (p < 0.0001) difference between the two 
groups. 
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Western blot analyzes were done to confirm the presence of 21OH-aab in plasma of AAD 
patients and its binding capacity to 21OH. Different lysates containing 21OH (Table 4.A) 
were separated by SDS-PAGE and blotted on a PVDF membrane before incubation with 
plasma. There were detected bonds for 21OH at ~54 kDa for the positive control (a 
commercial Anti-Human IgG/21OH polyclonal antibody) and Addison patient plasma 
identifying the presence of 21OH-aab (Figure 4.2.A). No bonds were detected for healthy 
control plasma. 
Total IgG was purified chromatographically by Protein A spin columns from patients and 
healthy control plasma with high levels of 21OH-aab where the yields are shown in Table 3. 
Plasma, purified total IgG and IgG depleted plasma were also analyzed to determine if plasma 
samples with variable contents of 21OH-aab would bind 21OH lysates (Table 4.B) and that 
purified IgG retained its 21OH binding capabilities (Figure 4.2.B). Plasma and purified IgG 
displayed strong bonds to 21OH lysates at ~54 kDa while IgG depleted plasma displayed 
weaker bonds. 
Table 3: Profit from IgG purification from 1.2 ml plasma. 
IgG concentration, mg/ml 
Patient Elution 1 Elution 2 
1 3.2 0.5 
7 4.2 0.3 
8 3.1 0.6 
9 3.7 0.7 
10 1.8 0.4 
24 4.8 - 
25 3.4 0.7 
26 4.0 0.6 
27 2.2 0.3 
28 2.2 0.5 
29 1.9 0.2 
30 2.0 0.2 
31 3.8 0.2 
32 4.4 0.5 
34 3.2 0.6 
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Figure 4.2: Western blot analysis confirmed the presence of 21OH-autoantibodies in AAD plasma and 
purified IgG. 21OH lysates were separated on a PVDF membrane to determine the presence of 21OH-aab in 
plasma and purified IgG. AP-conjugated goat Anti-Human IgG was used as secondary antibody and 
SeeBlue®Plus2 Prestained standard were used for both blots. The blots represent one individual experiment each. 
A: 21OH (54 kDa) was detected right upon the third standard bond at 51 kDa (Glutamic Dehydrogenase) 
indicating the presence of 21OH-aab. The positive control and patient 1 both detected bonds at ~54 kDa 
confirming the presence of 21OH-aab. Plasma from healthy control did not contain 21OH-aab. B: Identification 
of 21OH-aab in plasma and purified IgG from patient 1. IgG depleted plasma also seemed to contain some 
residual 21OH-aab. 
 
 
Table 4: 21OH-containing protein preparations used for Western blot analyzes 
A Patient plasma 
Sample 1 Purified microsomes from insect cells containing recombinant 21OH 
Sample 2 NCI-H295R lysate (adrenocortical carcinoma cell line expressing 21OH) 
Sample 3 Purified21OH from E. coli (lower molecular weight due to removal of 
some of the protein) 
Sample 4 Purified microsomes from insect cells without recombinant 21OH 
B Purified IgG 
Sample 1 Purified microsomes from insect cells containing recombinant 21OH 
Sample 2 21OH from E. coli (lower molecular weight due to removal of some of the 
protein) 
Sample 3 Purified microsomes from insect cells without recombinant 21OH 
Sample 4 Recombinant 21OH expressed and purified from insect cells. 
4.2 IFN-γ production enhanced by 21OH-autoantibodies 
Peripheral blood mononuclear cells (PBMC) were directly pre-stimulated with 21OH ± IgG in 
immune complexes after thawing to investigate if IgG could increase the uptake of 21OH into 
APC and subsequently enhance the T-cell response as measured by IFN-γ. Eight independent 
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ex-vivo ELISPOT analyses showed an increased number of spots detected after stimulation of 
21OH in presence of IgG. However, a two-tailed paired T-test showed no significance (n.s.) 
but only a relative trend between the groups; un-stimulated cells vs. pre-stimulated with 
immune complex (p = 0.056) and 21OH alone vs. immune complex (p = 0.063) (Figure 4.3 
and Figure 4.4). 
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Figure 4.3: IFN-ɣ production in response to 21OH ± IgG stimulation of PBMC. PBMCs from AAD patients 
(n=8) were stimulated with 21OH ± IgG for 24 hours in independent experiments and spots due to IFN-γ 
production was measured by ELISPOT. Each dot represents the average of one patient with 3-4 parallels and the 
line represents mean of all patients for each stimuli. Two-tailed paired T-test was performed, however no 
significance (n.s.) was detected between the groups; Blank vs. 21OH/IgG (p = 0.056), 21OH vs. 21OH/IgG (p = 
0.063), identifying only a trend of 21OH-aab. 
 
Figure 4.4: Independent representative ex-vivo ELISPOT`s with enhanced T-cell response due to 
21OH/IgG pre-stimulation. PBMC from individual patients pre-stimulated with 21OH ± IgG for 24 hours 
showed an increased IFN-γ production and T-cell response against 21OH/IgG. Significance was tested by A: a 
two-tailed paired T-test (p = 0.041) between 21OH alone vs. 21OH/IgG with four parallels per sample. B: a 
paired two-tailed paired T-test (p = 0.095) between Blank vs. 21OH/IgG with three parallels per sample, n.s. C: 
two-tailed paired T-test with three parallels per sample, n.s. 
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Spots produced by activated T-cells were manually counted in a microscope for the ex-vivo 
ELISPOT. Typical appearances of the ELISPOT wells are displayed in Figure 4.5. 
 
Figure 4.5: Ex-vivo ELISPOT illustrating detected IFN-γ spots after pre-stimulation with 21OH alone and 
21OH/IgG immune complexes. Increased amounts of spots were detected for immune complexes (right image, 
11 spots) compared to 21OH alone (left image, 4 spots) in patient 1 where each spot represent one IFN-γ 
producing cell. 
 
4.3 Importance of Fcγ-receptors in T-cell response 
4.3.1 Blocking of FcγRII (CD32) and FcγRI (CD64) in PBMC 
For selected patients, Fcγ-receptors (FcγR) on PBMC were blocked by Anti-FcγRI (CD64) 
and II (CD32) before cells were stimulated with 21OH ± IgG. IFN-γ production was 
measured by ex-vivo ELISPOT as described above and the blocking of FcγRs lead to a 
decreased T-cell response for one of the patients (Figure 4.6). 
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Figure 4.6: The importance of Fcγ-receptors on PBMC. Fcγ-receptors on PBMC from patient 10 were 
blocked by Anti-CD32 and Anti-CD64 (Fcγ-receptor II and I) for 1 hour before stimulation with immune 
complexes. Cells were stimulated for 24 hours until IFN-γ production was measured by ex-vivo ELISPOT. A 
decreased T-cell response was detected in the presence of blocking antibodies against the Fcγ –receptors. The 
decrease did not reach statistical significance by a two tailed paired T-test however; 21OH+IgG vs. Anti-CD32 
(p=0.353) and 21OH+IgG vs. Anti-CD64 (p=0.519). 
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Ex-vivo ELISPOT with blocking antibodies against FcγRs was performed for two more 
patients. However, none of these two patients showed any IFN-γ response against either 
21OH or 21OH/IgG immune complexes, even in the absence of FcγR blockade (results not 
shown). 
4.3.2 Antigen presenting cells and the uptake of immune complexes 
4.3.2.1 Expression of Fcγ-receptors on APC by flow cytometry 
Initially, the expression of FcγRs on different APC was determined by flow cytometry to 
confirm our hypothesis that the immune complexes are ingested by FcγRs. 
Priess cells are an immortalized B-cell line and it was of interest to investigate if they express 
FcγRs CD32 and CD64 on their surface where 21OH-aab may bind. Unstained cells were 
used as a negative control and a gate was set up for cells staining positive for FcγRs. Only 
CD32 was detected in Priess cells (Figure 4.7). 
 
Figure 4.7: Flow cytometry analysis for detection of Fcγ-receptors on Priess cells. The expression of Fcγ-
receptors CD32 and CD64 in Priess cells was assessed by flow cytometry using indirect staining with 
unconjugated mouse Anti-CD32 and Anti-CD64 primary antibodies, and Alexa488-conjugated donkey Anti-
Mouse as secondary antibody. Priess cells were treated with Fc-blocker to avoid unspecific binding to the Fc-
receptors prior to staining. A: Gating of live cells using their forward and side scatter properties, allowing only 
live cells to be analyzed for fluorescence. B: Background (PRIESS cells with secondary antibodies). C: 
Quantification of Priess cells expressing CD32 treated with Anti-CD32 and Alexa488-conjugated secondary 
antibody. D: Quantification of Priess cells expressing CD64 treated with Anti-CD64 and Alexa488-conjugated 
secondary antibody. Except for A, the X-axis represents the size of the cells and the Y-axis the fluorescence 
intensity of Alexa488. 
 
Monocytes were purified by CD14 Microbeads from PBMC prior to the flow cytometry 
experiment. Flow cytometry was performed after culturing for 24 hours with or without the 
presence of IFN-γ. The expression of FcγRs was considerable increased due to IFN-γ 
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stimulation and unlike the first experiment CD64 was even higher expressed than CD32 
(Figure 4.8). 
 
 
 
Figure 4.8: Flow cytometry determined expression of Fcγ-receptors on monocytes. The expression of Fcγ-
receptors CD32 and CD64 in monocytes was conducted by flow cytometry using Alexa488-conjugated Donkey 
Anti-Mouse as secondary antibody. Monocytes were incubated with Fc-blocker and primary antibody 
CD32/CD64 (1:100) prior to detection and selected cells were stimulated with IFN-γ for 24 hours in advance. 
A/E: Gating of live monocyte populations allowing only live cells to be analyzed for fluorescence. B/F: 
Background (monocytes and secondary antibody only). C/G: Quantification of monocytes expressing CD32 
stained with Anti-CD32 and Alexa488-conjugated secondary antibody. D/H: Quantification of monocytes 
expressing CD64 stained with Anti-CD64 and Alexa488-conjugated secondary antibody. Except for A/E, the X-
axis represents the size of the cells and the Y-axis the fluorescence intensity of Alexa488. 
 
 
Primary B-cells may also have uptake of immune complexes on the basis of their expression 
of FcγR`s. To analyze this, we purified B-cells from PBMC by CD19+ Dynabeads®. The 
purified B cells were then cultured for 24 hours with or without the presence of IFN-γ. The B-
cells expressed CD32 at quite high levels, even in the absence of IFN-γ, which only increased 
the expression slightly. Interestingly, however, the B cells did not express CD64 regardless of 
the presence or absence of IFN-γ (Figure 4.9). 
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Figure 4.9: Flow cytometry analysis of B-cells and their expression of Fcγ-receptors. Purified B-cells was 
treated with Fc-blocker and Anti-CD32/64 prior to incubation with Alexa488-conjugated seconday antibody for 
fluorescence detection in flow cytometry. A/E: Gating of live B cell populations. B/F: Background (B-cells 
stained with secondary antibody only) C/G: Expression of CD32 receptor on B-cells. D/H: Expression of CD64 
receptors on B-cells. The X-axis represents the size of the cells and the Y-axis the fluorescence intensity of 
Alexa488. 
 
4.3.2.2 Ex-vivo ELISPOT measuring T-cell response in different populations of 
APC 
After detection of FcγRs on the various cell types it was of interest to look at the T-cell 
responses with monocytes and B cells as APC. The effect of FcγRs in a T-cell response was 
determined for Priess cells and primary monocytes and B-cells. 
Priess cells were incubated with 21OH ± IgG to allow for uptake of the immune complex, and 
equal amounts of Priess cells and PBMC were cultured together for 24 hours in an ELISPOT 
assay. A significantly increased T-cell response was observed in the presence of 21OH/IgG 
immune complexes compared to 21OH alone (Figure 4.10). 
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Figure 4.10: Effect of immune complex-stimulated Priess cells in an ex-vivo ELISPOT. Priess cells were 
stimulated for 1 hour with IgG alone, 21OH alone, or 21OH/IgG immune complex prior to PBMC addition from 
patient 4. Increased T-cell response was significantly (p = 0.044) determined by a two-tailed paired T-test 
between the two groups with four parallels for each stimulation. 
Purified monocytes (CD14
+
) were treated with IFN-γ (1 µg/ml) and cultured for 24 hours 
until stimulation with immune complex and Anti-CD32/64 to block respective FcγRs. 
Autologous CD4
+
 T-cells were then isolated and added to the monocytes three hours after the 
addition of immune complexes. A considerable increased T-cell response was observed for 
patient 34 (Figure 4.11.A) stimulated with immune complex compared with 21OH alone, with 
a subsequently decreased response after FcγR blockage. For patient 7, no specific T-cell 
response against 21OH was observed, regardless of the presence of IgG (Figure 4.11.B). 
 
Figure 4.11: Fcγ-receptor dependent increase in CD4+ T-cell responses against 21OH/IgG immune 
complexes using monocytes as APC. Purified monocytes were stimulated with IFN-γ for 24 hours to up-
regulate the expression of Fcγ-receptors, pulsed with 21OH or 21OH/IgG in the absence or presence of Anti-
CD32/64, and used as APC for purified autologous CD4+ T-cells. A: Patient 34 showed an increased response to 
the immune complex and a correlated decrease due to blocking of Fcγ-receptors. However n.s. was determined 
between Blank and 21OH/IgG after a two-tailed paired T-test (p = 0.422) with three parallels per sample. B: For 
patient 7 no cellular responses above background against either 21OH or the immune complex were detected. 
Instead, a rather high response against IgG alone was noted. 
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A similar protocol as for monocytes was performed for B-cells with IFN-γ stimulation prior to 
addition of Anti-CD32/64 and immune complex before incubated with autologous CD4
+
 T-
cells. Cells from one of the same patients as in the monocyte experiment (patient 7) were 
used. Unfortunately, again no specific responses against 21OH or the immune complex were 
detected for this patient (Figure 4.12). 
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Figure 4.12: No Fcγ-receptor dependent increase in CD4+ T-cell responses against 21OH/IgG immune 
complexes using B-cells as APC. B-cells from patient 7 were stimulated with IFN-γ for 24 hours, pulsed with 
21OH and 21OH/IgG immune complex and used as APC with purified autologous CD4+ T-cells. Again, an 
apparent response against IgG alone was noted, but no specific responses against either 21OH or 21OH/IgG. 
Two-tailed paired T-test was n.s. 
4.4 T-cell line and recognition of 21OH peptides 
4.4.1 Effect of stimulating PBMC with peptides of 21OH 
As we now had shown that immune complexes containing 21OH could be ingested into an 
APC to enhance T-cell immune responses, we next wanted to investigate whether the 21OH-
derived peptides presented by the APC is altered in the presence of immune complexes. 
Initially we used a panel of 21OH-derived peptides to detect peptides capable of invoking 
IFN-γ responses. Ex-vivo Elispot with PBMC was conducted as before and stimulated with 
single peptides or peptide pools of 21OH for 24 hours. For the analyzed patients the peptide 
pools p17-23, p31-38 and the peptide p34 gave a detectable T-cell response (Figure 4.13). 
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Figure 4.13: PBMC stimulated with 21OH-peptides for detection of possible T-cell activation by ex-vivo 
ELISPOT. PBMC was stimulated with peptides of 21OH for 24 hours and IFN-γ spots were counted by ex-vivo 
ELISPOT. A: Patient 25 was stimulated with p34 and the pool p31-38 (except p34) and three parallels per 
sample were used. A specific response was observed against both p34 and the pool p31-38. B: Patient 26 was 
stimulated with peptides covering almost the whole 21OH-peptide sequence, but p17-23 was the only peptide 
pool which gave a specific response. Three parallels per stimulation were analyzed. 
 
In order to confirm the ex-vivo ELISPOT analysis an IFN-γ ELISA was conducted with 
supernatants from the stimulated PBMC from patient 26. ELISA gave similar results as 
ELISPOT with p17-23 being the only peptide pool inducing IFN-γ production in this patient ( 
Figure 4.14). 
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Figure 4.14: IFN-γ ELISA of supernatants from stimulation of immune complex and 21OH-peptides from 
the ex-vivo ELISPOT. Supernatants from ex-vivo ELISPOT (Figure 4.13) was incubated on a 96 well plate 
coated with Anti-IFN-γ capture antibody and detection of IFN-γ was performed by IFN-γ ELISA A notable 
increased level of IFN-γ was detected for peptide pool p17-23 which was over 6 folds above un-stimulated cells. 
IFN-γ (pg/ml) was calculated from a logarithmic standard curve. 
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4.4.2 T-cell lines induced by mature dendritic cells pulsed with 21OH alone 
or in immune complex with IgG 
In order to investigate if autoantibodies against 21OH could influence the processing and 
presentation of 21OH-derived peptides, we established short term T-cell lines using mature 
dendritic cells (DC) pulsed with 21OH alone, or 21OH/IgG immune complexes.  
The resulting T-cell lines were then tested in a re-stimulation step with 21OH-derived 
peptides. A considerable increase in IFN-ɣ producing cells was detected for p34 and p17-23 
for T-cell lines established using immune complex pulsed mature DC, indicating that 21OH-
aab might be important for the processing and presentation of these peptides (Figure 4.15 A). 
ELISA was also performed using the supernatants from the re-stimulated T-cell lines. These 
results also show an increase in IFN-γ responses for T-cells stimulated by DC pulsed with 
21OH and IgG autoantibodies (Figure 4.15 B). 
 
Figure 4.15: Only 21OH-specific T-cell lines induced in the presence of 21OH-autoantibodies recognize 
peptides p34 and p17-23. Adherent PBMC were differentiated into mature dendritic cells (DC) and pulsed with 
21OH ± IgG. Autologous PBMC were then added in order to establish 21OH-specific short term T-cell lines. 
After 7 days these T-cell lines were tested against 21OH-derived peptides in an ELISPOT assay, using 
autologous PBMC as APC. A: Peptides spanning the whole 21OH-peptide sequence were tested but only p34 
and p17-23 gave a raised T-cell response in the T-cell lines using ELISPOT. B: IFN-γ ELISA was performed by 
supernatants from the ELISPOT cultures, and showed the same results: Only T-cell lines raised against the 
21OH/IgG immune complex could recognize peptides p34 and p17-23. 
 
4.4.3 CD4+ T-cell lines induced by mature dendritic cells pulsed with 21OH 
alone or in immune complex with IgG 
An analogous experiment as outlined above (chapter 4.4.2) was performed, except that instead 
of using PBMC as the source of T-cells, purified CD4
+
 T-cells were used. Even though a 
broad T-cell response was detected, no increased T-cell responses were detected against any 
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peptides with CD4
+
 T-cell lines raised against 21OH/IgG immune complexes compared to 
21OH alone (Figure 4.16). 
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Figure 4.16: No increase in T-cell responses of CD4
+
 T-cell lines was raised against 21OH/IgG immune 
complexes compared to 21OH alone. Adherent PBMC from patient 30 were differentiated into mature 
dendritic cells (DC) and pulsed with 21OH ± IgG. Autologous CD4+ T-cells were then added in order to 
establish 21OH-specific short term T-cell lines. After 9 days, these T-cell lines were tested against 21OH-
derived peptides in an Elispot assay, using autologous PBMC as APC. Two parallels per sample were used. 
 
4.5 Measurement of T-cell cytotoxicity induced by CD8+ T-cells 
After measurement of cytokine production in response to stimulation with 21OH, it would be 
interesting to look at another T-cell response, such as cytotoxicity. We therefore assessed the 
ability of cytotoxic T-cells raised against 21OH or 21OH/IgG immune complexes to kill 
target cells expressing 21OH endogenously, or pulsed with 21OH-derived peptides. 
4.5.1 Detection of HLA-A2 expression in NCI-H295R 
As effector and target cells must express the same HLA molecule in order to be used together 
in cytotoxicity assays, we performed immunofluorescence to determine the expression of 
HLA-A2 in NCI-H295R cells.  
NCI-H295R cells were grown on coverslips and stimulated with IFN-γ (1 µg/ml) ahead of 
fixating of cells and staining for HLA-A2 expression. Cells stimulated with IFN-γ had a 
higher expression of HLA-A2 (C) compared to cells grown under basal conditions (B). Cells 
incubated with secondary antibody only (A) did not show any specific staining (Figure 4.17). 
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Figure 4.17: Detection of class I HLA-A2 in NCI-H295R target cells by immunofluorescence. NCI-H295R 
cells were grown on coverslips, fixed with 4 % formaldehyde and stained with mouse Anti-Human HLA-A2 (2 
µg and 1 µg), followed by Alexa488-conjugated donkey Anti-Mouse. Cells treated with IFN-γ had a higher 
expression of HLA-A2 compared to basal conditions. A: Background, only cells and DAPI with 2 µg primary 
antibody. B: Basal Anti-HLA-A2 with 2 µg primary antibody. C: Anti-HLA-A2 + IFN-y (1µg/ml) with 2 µg 
primary antibody. Blue = DAPI (nucleus), green = Alexa488 (HLA-A2). 
 
Flow cytometry was also performed for detection of HLA-A2 in NCI-H295R cells for a 
more quantitative analysis. Priess cells also express HLA-A2 and were used as positive 
control (Figure 4.19). As expected the NCI-H295R cells expressed the HLA-A2 molecule 
and cells stimulated with IFN-ɣ in advance showed an increase in HLA-A2 expression 
(Figure 4.18). 
 
 
Figure 4.18: Detection of HLA-A2 subclass on NCI-H295R target cells by flow cytometry. NCI-H295R 
cells were stained with FITC-conjugated mouse Anti-HLA-A2 antibodies for flow cytometry. A gate was set for 
unstained cells to detect HLA-A2 expressing cells. The X-axis represents the granulation of the cells and the Y-
axis the fluorescence intensity of FITC. 
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Figure 4.19: Detection of HLA-A2 in Priess cells used as positive control in flow cytometry. Priess cells 
were stained with FITC-conjugated Mouse Anti-HLA-A2. The X-axis represents granulation of the cells and the 
Y-axis the fluorescence intensity of FITC. 
 
4.5.2 Cytotoxicity induced by 21OH-specific CD8+ T-cells 
Prior to measuring the cytotoxicity produced by CD8
+
effector T-cells, the optimal triton 
concentration used as positive control and the number of target cells; NCI-H295R was 
determined. NCI-H295R cells were cultured to an adequate cell number and two levels of cell 
density were added various concentrations of Triton X-100 to find the best and most sensitive 
condition using LDH release as a marker for cytotoxicity.  
The LDH release was detected for the cell density at 5*10
4
 cells with 0.1 % Triton. Despite of 
this the 2*10
4
 cell density was chosen because of the difficulty in work up of a sufficient 
number of CD8
+
 T-cells for the highest cell density of target cells (Figure 4.20). 
0.
00
1 
%
0.
01
 %
0.
1 
%
0.
2 
%
0
200
400
600
800
1000
H295R 2*10^4
H295R 5*10^4
Triton concentration
L
D
H
 c
o
n
c
e
n
tr
a
ti
o
n
 (
p
U
)
 
Figure 4.20: Modification of cytotoxicity experiment measuring released LDH from NCI-H295R target 
cells. Two cell density populations of NCI-H295R were cultured and treated with various concentrations of 
Triton X-100 in order to modify the cytotoxicity method. Release of LDH into cell culture media was measured 
at a spectrometer at 490 nm. X-axis represents raised Triton concentrations and Y-axis the concentration of LDH 
released into the medium. 
Results 
45 
 
 
Again, we established short term T-cell lines using mature DCs pulsed with 21OH alone, or 
21OH/IgG immune complexes. This time, however, purified CD8
+
 cells were used as the 
source of T-cells. The resulting T-cell lines were then tested in a LDH cytotoxicity assay with 
NCI-H295R cells as target cells. After modifications NCI-H295R cells (2*10
4 
cells) were 
stimulated with IFN-γ (0.5 µg/ml) and then incubated with the cultured CD8+ T-cell lines for 
4 hours. Supernatants were transferred to a Nunc-96 well plate with standards and the LDH 
content was measured by adding substrate and reading the absorbance by spectrometry at 490 
nm (Figure 4.21). 
 
Figure 4.21: Cytotoxic effect of CD8
+
 T-cells against NCI-H295R target cells. NCI-H295R cells were 
incubated with IFN-γ (0.5 µg/ml) to increase the HLA-I expression and used as target cells for CD8+ T-cells 
specific for 21OH. The X-axis represents ratio between effector and target cells and Y-axis concentration of 
released LDH into cell culture medium. A: Patient 27 was pre-stimulated with IgG alone and IgG/21OH. B: 
CD8+ T-cells from patient 28, stimulated with mature DCs pulsed with 21OH/IgG autoantibody showed a 
slightly higher rise in cytotoxicity than those raised against 21OH alone. 
 
The cytotoxicity study was also performed with 21OH-peptide pulsed PBMC as target cells 
for CD8
+
 T-cell lines. CD8
+
 T-cell lines were established as described above, using mature 
DC pulsed with 21OH alone or 21OH/IgG immune complexes. Then, an autologous PBMC 
suspension pulsed with peptide pools of 21OH-derived peptides were used as target cells for 
the CD8
+
 T-cell lines in a 4 hour cytotoxicity assay as described above for the NCI-H295R 
cells (Figure 4.22). 
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Figure 4.22: Increased cytotoxicity of CD8
+
 T-cell lines against 21OH/IgG immune complexes compared 
to 21OH alone. Mature DC were pulsed with 21OH ± IgG and used to establish CD8+ T-cell lines. Autologous 
PBMC were used as target cells after pulsing with 21OH-derived peptide pools (at 10 µg/ml) in a 4 hour LDH 
cytotoxicity assay with different ratios of CD8+ T-cells. The X-axis represents the stimulation of peptides in 
different effector:target cell ratios and Y-axis is LDH concentration released to cell culture medium calculated 
from the linear equation from the standard curve. 
 
IFN-γ ELISA was also performed from the supernatants from the cytotoxicity study and the 
results correlated only partially with the data from the cytotoxicity assay (Figure 4.22) (results 
not shown). 
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5. Discussion 
Addison`s disease is an organ specific autoimmune disease thought to develop because of a 
cell mediated immune response against the adrenal cortex. Although autoantibodies against 
21OH and the adrenal cortex are highly characteristic for the disease, their role in the 
pathogenesis is largely unknown. A previous study showed a possible involvement of 21OH-
autoantibodies (21OH-aab) in the enhancement of T-cell responses against 21OH [40]. 
This project aimed to further investigate if 21OH-aab in Addison`s patients enhance the 
uptake of 21OH into antigen presenting cells (APC) trough Fcγ-receptors (FcγRs) and 
subsequently increase the activation of autoreactive T-cells. Ex-vivo T-cell responses from 
PBMC were determined after pre-stimulation with 21OH ± 21OH-aab. T-cell responses were 
also investigated in the presence of blocking antibodies against the FcγRs and with purified 
subsets of APC. Furthermore, T-cell lines were established using mature DC pulsed with 
21OH alone or in 21OH/IgG immune complexes. These T-cell lines were then compared by 
testing their reactivity against a panel of 21OH-derived peptides.  
The main discovery was the clear enhancement of ex-vivo T-cell responses when stimulated 
with 21OH in the presence of autoantibodies. This enhancement seemed to be FcγR 
dependent. Furthermore, T-cell lines generated by mature DC pulsed with 21OH/IgG 
complexes showed an enhanced IFN-γ response against 21OH or 21OH-derived peptides, 
compared to T-cell lines generated by mature DC pulsed with 21OH alone. 
5.1 Detection of 21OH-autoantibodies 
Addison`s patients are characterized by the presence of serum antibodies against the self-
antigen 21OH, exclusively expressed in the adrenal cortex. We therefore started with the 
detection of such autoantibodies in our patient cohort, using an indirect ELISA based on 
purified 21OH recombinant protein as described [51]. This assay clearly distinguished 
between plasma samples from patients and healthy controls (Figure 4.1), but also revealed 
quite heterogeneous levels of autoantibodies between patients. We therefore selected plasma 
samples that contained high levels of autoantibodies for IgG purification (Table 3). 
Furthermore, Western blot analysis confirmed the presence of 21OH-aab in AAD plasma and 
its binding capacity to the 21OH enzyme. Various protein preparations containing 21OH, 
either recombinant or naturally expressed (Figure 4.2.A) were all recognized by patient 
plasma and a polyclonal control antibody against 21OH, but not by plasma from healthy 
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controls. No antibodies were detected against the negative control, sf9 insect cell lysates, 
which is an insect cell line used for production of recombinant 21OH [51].  
Subsequently, plasma with high levels of 21OH-aab, as detected by ELISA and Western blot, 
were used for the purification of IgG. Another Western blot analysis was performed to 
validate that 21OH binding capabilities were contained in the purified IgG fractions. Plasma 
and purified IgG showed the expected bonds around 54 kDa identifying 21OH-aab (Figure 
4.2.B). Despite weak bonds observed for plasma without IgG, which demonstrates an 
incomplete depletion of IgG in plasma by the purification method used, stronger bonds were 
detected for purified IgG confirming a sufficient level of purified 21OH-specific IgG. 
Actin or a similar control could have been used as a control for comparing the strength of the 
different bands from different samples (e.g. purified IgG vs. whole plasma vs. IgG depleted 
plasma). On the other hand the main purpose of this experiment was to determine the actual 
presence and binding capacity of 21OH-aab to 21OH in the purified IgG fractions. Also, 
equal amounts of 21OH protein were loaded on the SDS-PAGE gels for each sample. 
5.2 IFN-γ production enhanced by 21OH-autoantibodies 
Bratland et al [40] have previously reported a possible role for 21OH-aab in activating 21OH-
specific autoreactive T-cells in AAD. It was therefore of great interest to take this a step 
further with a more sensitive method – ex-vivo ELISPOT. Cytokine production are often 
measured by ELISA due to cytokine release into cell culture medium [53] requiring an in 
vitro stimulation which will not give a direct analysis of PBMC [54]. ELISPOT is then 200 
times more sensitive and have been used to determine cytokine profiles in e.g. T-cell subsets  
[55]. The ELISPOT assay used has previously been shown to clearly distinguish between 
AAD patients and healthy controls (unpublished, Bratland et al.). 
In the present study, we also used more stringent criteria with a defined serum-free medium, 
which means that the only IgG molecules present were those purified from patient plasma. In 
the presence of 21OH-aab associated with 21OH in an immune complex, a significantly 
increased IFN-γ production was detected among PBMC (Figure 4.4.A), indicating that 21OH-
aab have a significant role in activating 21OH-specific autoreactive T-cells.  
Eight ex-vivo ELISPOT experiments were performed where seven AAD patients showed a 
specific T-cell response against 21OH in complexes with 21OH-aab (Figure 4.3). Even 
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though ex-vivo ELISPOT is among the most sensitive methods for these kinds of experiments, 
it may not be sensitive enough to detect frequencies lower than 1 cell per million PBMC. 
Also, we used a very heterogeneous group of patients for these studies, with disease durations 
ranging from two months to over 40 years. At such long disease duration, remaining 
adrenocortical tissue is probably non-existent, and 21OH-specific autoreactive T-cells may be 
extremely infrequent. However, a subset of patients showed a clear response to 21OH and 
intriguingly these responses were further increased with presence of 21OH-aab. 
5.3 Importance of Fcγ-receptors in T-cell response 
FcγRs expressed on APC are thought to have a role in uptake of immune complexes by 
binding to the Fc-part of IgG [56, 57]. Interestingly, blockage of these receptors on PBMC 
prior to pre-stimulation with immune complexes led to a decreased IFN-γ production (Figure 
4.6). FcγRs mediate a 50-100 times more efficient antigen uptake [58] in contrast to antigen 
internalization, due to their low antigen requirement [59]. Thus, the amount of antigen 
required for a full T-cell activation may be considerably less when present as an immune 
complex. This could initiate a possible T-cell response mechanism in AAD due to low levels 
of 21OH released out of the adrenal cortex to local lymph nodes to stimulate an immune 
response against 21OH. 21OH-specific autoantibodies produced by the resulting immune 
response might then migrate to the adrenal cortex and lead to a self-amplifying circuit and 
enhancement of the anti-21OH T-cell response. 
In order to decide which APC populations were involved in the enhanced T-cell response 
against immune complexes, the expression of the FcγR II (CD32) and I (CD64) on different 
APC populations was determined by flow cytometry. Priess cells, a B-cell line immortalized 
by Epstein-Barr virus infection, were shown to express CD32 receptors, but not CD64 (Figure 
4.7).The Priess cells could also induce IFN-γ production by HLA matched PBMC, but only 
when pulsed with 21OH as immune complex. No specific IFN-γ production was observed 
when 21OH was added alone (Figure 4.10). This suggests that uptake of 21OH is only 
possible via FcγRs in Priess B-cells, as B cells are usually poor phagocytes [8]. 
The expression of CD32 and CD64 in monocytes were very low (Figure 4.8.C, D), but 
increased considerably after IFN-γ stimulation (Figure 4.8.G and H) indicating that IFN-γ is 
able to stimulate cells to up-regulate the expression of FcγRs, which have been confirmed 
earlier [17, 60, 61]. Earlier studies have also seen expression of CD32 and CD64 in isolated 
monocytes where CD64 expression was significantly up-regulated in both monocytes and DC 
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due to IFN-γ stimulation for 24 hours [57]. IFN-γ stimulated monocytes also enhanced T-cell 
responses against 21OH when present as immune complex, but these responses decreased 
when blocking antibodies for the FcγRs where present. The decrease was most abundant for 
the CD64 receptor but the CD32 receptor also seemed involved (Figure 4.12). 
Previous studies [56] on B-cells have already shown expression of CD32 which correlates 
with our findings of expression patterns (Figure 4.9). B-cells were also tested in an ex-vivo 
ELISPOT to determine their antigen presenting capabilities of 21OH immune complexes in 
the absence and presence of blocking FcγRs. Unfortunately, for the patient tested in this 
particular experiment, no detectable IFN-γ response against either 21OH alone or 21OH/IgG 
could be measured (Figure 4.12). Instead, there seemed to be an IFN-γ response against IgG 
alone, which was also the case with monocytes for this particular patient (Figure 4.11). This 
finding is peculiar, but may reflect T-cell responses against idiotypic determinants in the 
antigen-binding sites of IgG antibodies. Such T-cells have been described in other 
autoimmune diseases such as multiple sclerosis [62]. 
A decreased cell response due to blockade of FcγRs on B-cells have also been observed in a 
mouse model of autoimmune diabetes where the Anti-islet IgG autoantibodies may induce a 
CD4
+
 T-cell mediated response eventually leading to disease [63]. 
To sum up, although based on few experiments, we can confirm a role in the induction of T-
cell responses against 21OH/IgG immune complexes by monocytes. The uptake of the 
immune complexes may occur through both CD32 and CD64. However, a similar role of 
primary B-cells cannot be excluded due to their strong expression of CD32 receptors, which 
can be correlated to the experiments with the Priess B cells and also to other earlier studies 
[56]. These experiments therefore need to be repeated with patients that have a specific IFN-γ 
response to 21OH (either isolated or as immune complex) to determine the role of primary B 
cells. 
To ensure the purities of the isolated APC subsets, flow cytometry could have been done 
ahead of the ex-vivo ELISPOT in use of Anti-CD19 for B-cells and Anti-CD14 for monocytes 
even though the purification methods we have used should give adequate purity. 
5.4 T-cell line and recognition of 21OH peptides 
As we now had established that immune complexes indeed have a role in enhancing T-cell 
responses to 21OH, we wanted to investigate whether the state of 21OH, e.g. alone or as part 
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of immune complexes, influence the epitopes of 21OH presented by APC. Again using ex-
vivo ELISPOT, we initially performed a screen with PBMC from patients with known HLA 
types against a panel of peptides of the 21OH sequence. The peptides were pooled with seven 
and eight peptides in each pool. As p34 (21OH aa430-447) is a known epitope for 21OH and 
have been identified as a great inducer of IFN-γ production [64] it was used alone to 
investigate its stimulating capabilities in our patients. As expected, p34 was one of the 
activating peptides of 21OH together with the pools p31-38 (-34) and p17-23 (Figure 4.13). In 
order to confirm the ex-vivo ELISPOT analyzes an IFN-γ ELISA was conducted with 
supernatants from the stimulated PBMC cultures. Even in use of two different methods in 
measuring cytokine production the same peptides of 21OH proved to elicit specific IFN-γ 
production ( 
Figure 4.14). 
In order to investigate if the stimulating peptides described above represented naturally 
processed and presented peptides from 21OH, and if 21OH-containing immune complexes 
could influence the presentation of the peptides, we established T-cell lines using mature DC 
pulsed with 21OH alone or 21OH in immune complex. The resulting lines were then tested 
against a panel of peptides comprising the whole 21OH sequence. As expected, p34 gave an 
increased T-cell response together with p17-23 (Figure 4.15.A), but only for the T-cell line 
primed with the immune complex. In addition, this T-cell line produced considerably more 
IFN-γ to 21OH immune complex, than the T-cell lines raised against 21OH alone. This could 
indicate that the 21OH-aab facilitate the natural processing and presentation of immunogenic 
21OH peptides when 21OH is phagocytized as an immune complex. IFN-γ ELISA was also 
conducted for this experiment showing the same trend with no response to peptides for T-cell 
lines raised against 21OH alone, but high responses for T-cell lines raised against immune 
complexes (Figure 4.15.B). However, the trend for each peptide was different between the 
two methods indicating that p17-23 activated T-cells produce more IFN-γ per cell than for 
cells stimulated with p34. This may reflect phenotypical differences between the responding 
T-cells (e.g. CD4
+
 vs. CD8
+
). 
Several studies that have looked into T-cell lines have determined an increased T-cell 
response against immune complex compared to stimulation with antigen alone, indicating that 
antigens are ingested into APC in an antibody dependent manner [65-67]. 
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Purified CD4
+
 T-cells were also used in a similar experiment as above, in order to establish 
CD4
+
 T-cell lines. However, no differences between the two T-cell lines could be detected, 
even though a broad and robust response against many peptides was noted (Figure 4.16).We 
speculate that this could be due to a technical error by not allowing an adequate incubation 
time with the substrate for the final development step in the ELISPOT assay. However, it 
could also be a natural variation reflecting the heterogeneous pattern observed previously for 
the AAD patients. 
5.5 Measurement of T-cell cytotoxicity by CD8+ T-cells 
After measurement of cytokine production it would be interesting to look at another T-cell 
response parameter, such as cytotoxicity, and whether the state of 21OH when given to APC, 
e.g. alone or as part of immune complexes, could influence the action of 21OH-specific 
cytotoxic CD8
+
 T-cells. 21OH-specific CD8
+
 T-cell lines were established as above, using 
mature DC pulsed with 21OH alone or 21OH as part of immune complexes with 21OH-aab`s. 
As target cells we used the adrenocortical carcinoma cell line NCI-H295R, which expresses 
21OH endogenously, or autologous PBMC pulsed with 21OH peptides. We knew from 
previously that the NCI-H295R cells carry the HLA A*0201 genotype which encodes the 
HLA A2 molecule (Professor SR Bornstein, University of Dresden, personal communication). 
This genotype is very common in the Western world, and is carried by 26.5 % of the 
Norwegian AAD patients [52]. 
Since the NCI-H295R cells are cancer cells, we first wanted to make sure that their expression 
of HLA A2 at the protein level was normal. Immunofluorescence showed a normal expression 
of HLA-A2 in NCI-H295R cells (Figure 4.17). Furthermore, a higher expression of HLA-A2 
was seen after IFN-γ stimulation, meaning that the gene expression of HLA class I could be 
influenced by cytokine stimuli (Figure 4.17 C). This difference in staining intensity was 
evident even though less primary antibody (1 µg) were used for IFN-γ treated cells than cells 
cultured under basal conditions (2 µg). 
Flow cytometry was also conducted for NCI-H295R cells with conjugated antibody to 
confirm the immunofluorescence analyses, and revealed the same pattern with rather high 
basal levels which could be driven even higher in the presence of IFN-γ (Figure 4.18). As 
Priess cells are known to express HLA-A2 they were used as positive control (Figure 4.19). 
These analyses confirm that NCI-H295R is suitable as target cells for HLA A2 restricted 
cytotoxic CD8
+
 T-cells. 
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LDH was used as marker for cytotoxicity due to its release into cell culture medium by dying 
cells. This is a fast and simple assay, and a harmless alternative to more conventional 
cytotoxicity assays based on radioactive isotopes, such as the chromium release assay [68] 
which has been a standard assay for CTL-measurements [15]. A modification of the 
cytotoxicity analysis was done were two levels of NCI-H295R cell density was treated with 
various concentrations of Triton X-100 to find the best and most sensitive condition. The 
highest cell death was detected for the cell density at 5*10
4
 cells with 0.1 % Triton. Despite 
this the 2*10
4
 cell density was chosen because of the difficulty in work up enough CD8
+
 T-
cells for the highest cell density of target cells (Figure 4.20). 
Patients with HLA-A2 genotype were chosen and CD8
+
 T-cell lines were established. These 
were incubated with NCI-H295R target cells (2*10
4
) in different ratios to determine a 
possible increase due to more cytotoxic T-cells. T-cell lines from both patients investigated 
increased LDH concentrations with higher CD8
+
 T-cell ratios; however the response was 
generally very low, making it hard to determine if the immune complexes containing 21OH 
played a significant role in inducing cytotoxic 21OH-specific CD8
+
 T-cells. One of the T-cell 
lines from patient 27 was by mistake raised against IgG alone instead of 21OH, but as this T-
cell line differed only marginally from 21OH/IgG induced T-cell lines in its cytotoxic 
potential, we may conclude that no specific cytotoxicity was induced in these experiments 
(Figure 4.21). Other studies have used higher ratios of cytotoxic T-cells, up to 50:1 [69] and 
100:1 [70] (compared to 10:1 in the present study) and this should be tested out in future 
studies. A more sensitive flow cytometry based method has also been established in our 
laboratory. This method uses differential fluorescent staining of live and dead cells ([10]), but 
due to time limitations we were not able to include this method in the present study. 
CD8
+
 T-cell lines were also raised from another patient against 21OH alone, or 21OH/IgG.  
All peptides of 21OH gave an increase in LDH activity, but a differential pattern was evident 
when comparing T-cell lines raised against 21OH alone vs. 21OH/IgG (Figure 4.22). Taken 
together, these data indicate that also CD8
+
 cytotoxic T-cells may be influenced by the state 
of which 21OH (alone or as part of immune complexes) is ingested by APC. A similar finding 
has previously been reported for the autoimmune disease primary biliary cirrhosis [66]. 
5.6 Future perspectives 
AAD is a rare disease with a poorly understood pathogenesis. In order to devise novel 
treatment options and possibly prevent the disease, a much more detailed understanding of the 
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molecular mechanisms is needed. Compared to related but more common autoimmune 
endocrine diseases like type 1 diabetes, very little research on cellular autoimmunity have 
been performed on AAD.  
As each experiment in this thesis was only performed on few patients, and the individual 
differences between patients are clear in some instances, the most interesting experiments 
should be reproduced. In particular IFN-γ stimulated B-cells with blockade of FcγRs need to 
be repeated with other AAD patients to draw a respective conclusion. Even though monocytes 
gave an increased IFN-γ response against 21OH in presence of 21OH-aab, these studies 
should also be repeated in a larger patient cohort. 
Due to the unsuccessful LDH measurements with a too low cellular response, perhaps 
because of the low target and effector cell ratio, the new flow cytometry method mentioned 
above should be used.  Hopefully, this method should give a more specific determination 
between live and dead target cells. Purified CD8
+
 T-cells should be cultured in order to 
generate a maximum expansion of 21OH-specific cells, allowing for a higher ratio of 
effector:target cells. This could be accomplished by pulsing with a higher IL-2 dose than we 
have used in our studies, in order to increase the CD8
+
 proliferation [71].  
For an even more specific experimental set-up 21OH-specific autoantibodies might have been 
isolated from autologous plasma of patients, [66] instead of using total IgG which contain 
several antibodies other than 21OH-specific IgG. Due to time limitations, however, we were 
not able to isolate such purified 21OH-aab for the present thesis. 
5.7 Conclusion 
21OH in immune complex with IgG autoantibodies showed a clearly enhanced T-cell 
response compared to 21OH alone in Addison`s patients. Monocytes were involved in such an 
increased T-cell response with a clear effect in the uptake of immune complex through their 
Fcγ-receptors. However, a similar role for B-cells cannot be excluded based on our current 
data. Furthermore, the autoantibodies also seem to be able to modulate which peptides of 
21OH that are processed and presented to T-cells by APC.  
To conclude, 21OH-autoantibodies may have an important role in the pathogenesis of AAD. 
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6. Appendix 
6.1 21OH sequence 
 
>sp|P08686|CP21A_HUMAN Steroid 21-hydroxylase OS=Homo sapiens GN=CYP21A2 
PE=1 SV=1 
MLLLGLLLLPLLAGARLLWNWWKLRSLHLPPLAPGFLHLLQPDLPIYLLGLTQKFGPI
YRLHLGLQDVVVLNSKRTIEEAMVKKWADFAGRPEPLTYKLVSKNYPDLSLGDYSL
LWKAHKKLTRSALLLGIRDSMEPVVEQLTQEFCERMRAQPGTPVAIEEEFSLLTCSIIC
YLTFGDKIKDDNLMPAYYKCIQEVLKTWSHWSIQIVDVIPFLRFFPNPGLRRLKQAIE
KRDHIVEMQLRQHKESLVAGQWRDMMDYMLQGVAQPSMEEGSGQLLEGHVHMA
AVDLLIGGTETTANTLSWAVVFLLHHPEIQQRLQEELDHELGPGASSSRVPYKDRARL
PLLNATIAEVLRLRPVVPLALPHRTTRPSSISGYDIPEGTVIIPNLQGAHLDETVWERPH
EFWPDRFLEPGKNSRALAFGCGARVCLGEPLARLELFVVLTRLLQAFTLLPSGDALPS
LQPLPHCSVILKMQPFQVRLQPRGMGAHSPGQNQ 
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6.2 21OH peptide sequence 
Provided by Professor Vincenzo Cerundolo at University of Oxford. Peptide pools used in 
experiments are displayed in different colors under. 
 
 
 
1 MLLLGLLLLPLLAGARLL
2 GARLLWNWWKLRSLHLPP
3 LHLPPLAPGFLHLLQPDL
4 LQPDLPIYLLGLTQKFGP
5 QKFGPIYRLHLGLQDVVV
6 QDVVVLNSKRTIEEAMVK
7 EAMVKKWADFAGRPEPLT
8 PEPLTYKLVSKNYPDLSL
9 PDLSLGDYSLLWKAHKKL
10 AHKKLTRSALLLGIRDSM
11 IRDSMEPVVEQLTQEFCE
12 QEFCERMRAQPGTPVAIE
13 PVAIEEEFSLLTCSIICY
14 SIICYLTFGDKIKDDNLM
15 DDNLMPAYYKCIQEVLKT
16 EVLKTWSHWSIQIVDVIP
17 VDVIPFLRFFPNPGLRRL
18 GLRRLKQAIEKRDHIVEM
19 HIVEMQLRQHKESLVAGQ
20 LVAGQWRDMMDYMLQGVA
21 LQGVAQPSMEEGSGQLLE
22 GQLLEGHVHMAAVDLLIG
23 DLLIGGTETTANTLSWAV
24 LSWAVVFLLHHPEIQQRL
25 IQQRLQEELDHELGPGAS
26 GPGASSSRVPYKDRARLP
27 RARLPLLNATIAEVLRLR
28 VLRLRPVVPLALPHRTTR
29 HRTTRPSSISGYDIPEGT
30 IPEGTVIIPNLQGAHLDE
31 AHLDETVWERPHEFWPDR
32 FWPDRFLEPGKNSRALAF
33 RALAFGCGARVCLGEPLA
34 GEPLARLELFVVLTRLLQ
35 TRLLQAFTLLPSGDALPS
36 DALPSLQPLPHCSVILKM
37 VILKMQPFQVRLQPRGMG
38 PRGMGAHSPGQNQ
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